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Abstract
In neurological diseases, the actions of microglia, the resident myeloid cells of the CNS parenchyma, may diverge from, 
or intersect with, those of recruited monocytes to drive immune-mediated pathology. However, defining the precise roles 
of each cell type has historically been impeded by the lack of discriminating markers and experimental systems capable of 
accurately identifying them. Our ability to distinguish microglia from monocytes in neuroinflammation has advanced with 
single-cell technologies, new markers and drugs that identify and deplete them, respectively. Nevertheless, the focus of 
individual studies on particular cell types, diseases or experimental approaches has limited our ability to connect phenotype 
and function more widely and across diverse CNS pathologies. Here, we critically review, tabulate and integrate the disease-
specific functions and immune profiles of microglia and monocytes to provide a comprehensive atlas of myeloid responses in 
viral encephalitis, demyelination, neurodegeneration and ischemic injury. In emphasizing the differential roles of microglia 
and monocytes in the severe neuroinflammatory disease of viral encephalitis, we connect inflammatory pathways common 
to equally incapacitating diseases with less severe inflammation. We examine these findings in the context of human studies 
and highlight the benefits and inherent limitations of animal models that may impede or facilitate clinical translation. This 
enables us to highlight common and contrasting, non-redundant and often opposing roles of microglia and monocytes in 
disease that could be targeted therapeutically.
Keywords Microglia · Monocyte-derived cells · Immune-mediated pathology · Neuroinflammation · Neurodegeneration · 
Encephalitis
Introduction
Inflammation of the central nervous system (CNS) is a fea-
ture of many neurological disorders including infectious, 
autoimmune, sterile inflammatory, demyelinating and 
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neurodegenerative diseases [35, 58, 140, 194, 288]. Tissue-
resident and infiltrating myeloid cells, such as microglia 
and monocytes, are recruited to foci of infection, injury or 
inflammation in many of these CNS pathologies (Fig. 1), 
suggesting a role for these cells in the pathophysiology of 
disease [29]. Microglia and monocytes are both members 
of the mononuclear phagocyte system that carry out essen-
tial tissue-specific functions, critical for homeostasis and 
the response against pathogen evasion [139, 159, 261, 299]. 
Although the precise contributions of microglia and mono-
cytes to tissue damage and repair in CNS disease remain 
poorly resolved, they nevertheless represent potential can-
didates for targeted therapeutics.
Microglia are tissue-resident macrophages of the CNS 
parenchyma. These cells arise from uncommitted  KIT+ 
erythromyeloid precursors [181, 316], which seed the 
brain from the yolk sac at embryonic day 9.5 in the mouse 
[126], well before other glial cells and the formation of 
the blood–brain barrier (BBB) [130, 181]. They are sub-
sequently renewed in situ independently of bone marrow 
(BM) hematopoietic stem cells (HSC) [3]. However, more 
recently, other views challenging the sole yolk sac origin of 
microglia have emerged [55].
In the healthy homeostatic CNS, microglia comprise 
the predominant myeloid population, followed by non-
parenchymal CNS macrophages [182], collectively called 
CNS- or border-associated macrophages (CAMs or BAMs) 
[20, 235, 259]. Relative to BAM/CAMs, microglia uniquely 
express transmembrane protein 119 (TMEM119) [26], hex-
osaminidase subunit beta (Hexb) [174, 214, 215], P2Y 
G-protein-coupled 12 (P2RY12) [41], sialic acid-binding 
immunoglobulin-type lectin H (Siglec-H) and Spalt-like 
transcription factor 1 (Sall1) [45], express low levels of 
CD45 compared to leukocytes outside the CNS, and have a 
distinct morphology and anatomical location [20, 163, 235, 
259, 317]. This makes their identification in the homeostatic 
brain fairly straight-forward. However, during inflammation 
in response to CNS perturbation, microglia become reactive 
or activated, a state in which they upregulate CD45, partially 
or totally retract their cytoplasmic extensions and increase 
their somatic volume to adopt a more amoeboid morphol-
ogy [266, 303]. Microglia are also joined by a substantial 
infiltrate of BM-derived monocytes [298], both of which 
similarly express typical myeloid markers [19, 204, 298, 
299, 332] (such as CD68, Fig. 1). This hampers the accurate 
discrimination of these cell types during neuroinflammation 
in the mouse and human CNS.
Monocytes are peripheral myeloid cells derived from 
the fetal liver during embryogenesis and are continuously 
renewed throughout postnatal life from HSCs in the adult 
BM [115]. In the mouse, ‘inflammatory’ monocytes  (Ly6Chi) 
and ‘patrolling’ monocytes  (Ly6Clo) have been identi-
fied [114]. In humans, 'classical' monocytes (equivalent to 
 Ly6Chi monocytes in mice) make up the majority of the cir-
culating monocyte pool, with the remaining portion made 
up by intermediate and ‘non-classical’ monocytes  (Ly6Clo 
monocytes in mice) [251].
During homeostasis, circulating  Ly6Chi monocytes traffic 
through semi-permeable CNS regions, such as the choroid 
plexus and dura mater, where they increase the local com-
plexity of BAMs [128, 317]. The BBB prevents the infiltra-
tion of monocytes and other peripheral immune cells into 
the CNS parenchyma under homeostatic conditions [230]. 
During inflammation, however, BBB breakdown and leaki-
ness permits the infiltration of monocytes into the paren-
chyma. Such infiltrating monocyte-derived cells (MC), like 
monocyte-derived macrophages (MDM) and dendritic cells 
(moDC), can adopt a microglia-like phenotype upon entry 
into the inflamed brain. While these cells do not necessar-
ily upregulate genes expressed by homeostatic microglia 
[25, 66], the phenotypic similarities between populations of 
resident and infiltrating myeloid cells may approximate one 
another in neuroinflammation, hampering accurate identi-
fication of their respective functions in disease [298, 299].
Animal models employing more recent and precise exper-
imental approaches, such as microglia-depletion drugs, cell 
type-specific markers, gene silencing, lineage tracing, and 
in vivo imaging techniques, have been used to distinguish 
microglia and monocytes in various neuropathologies to 
understand their functional roles [26, 88, 91, 214, 220, 299, 
343]. While animal models may fail to fully replicate all 
aspects of human disease, they have been indispensable 
in understanding specific pathogenic mechanisms and the 
effect of therapeutics on particular aspects of disease. We 
now understand microglia and monocytes to be highly het-
erogeneous in phenotype and function, having both protec-
tive and pathogenic roles that contribute to disease onset, 
progression and/or recovery.
Here, we integrate and contrast human and animal find-
ings from studies investigating viral encephalitis, CNS 
injury, neurodegenerative disease and autoimmune neuro-
inflammation to elucidate key agonistic and antagonistic 
features of microglia and their BM-derived monocyte coun-
terparts across these neuropathologies. We focus on studies 
using more selective approaches, including transcriptomic 
profiling, high-dimensional cytometry and myeloid cell 
depletion to more accurately dissect their functional roles 
in neurological disease. In doing so, we identify common 
pathogenic or protective cell type-specific functions and 
phenotypes that may aid the development of targeted thera-
peutics across CNS diseases.
Viral encephalitis
Neuroinflammation resulting from viral infection of the 
CNS parenchyma (i.e., viral encephalitis) carries  ~ 5–30% 
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Fig. 1  Macrophage/microglial CD68 tissue staining in human CNS 
pathologies. Ameboid (solid arrows, likely macrophages and/or reac-
tive microglia) and ramified (open arrows, likely microglia)  CD68+ 
myeloid cells are shown in various neuropathologies: a West Nile 
virus (WNV) [247]. Macrophage/microglia engulfing a degenerat-
ing neuron (arrowheads) in the substantia nigra in a patient with ful-
minant WNV encephalitis (400X magnification). b Cortical stroke 
[94]. Foamy macrophages/microglia are present in a cerebral infarct 
(several weeks old) (scale bar represents 50 μm). c Parkinson disease 
(PD) [65]. Ramified microglia and macrophages with enlarged cyto-
plasm and short stout processes are present in the substantia nigra 
(400X magnification). d–f Amyotrophic lateral sclerosis (ALS) [38]. 
The three images show the variable extent of microglia activation in 
the corticospinal tract in patients with ALS assessed as either mild 
(d), moderate (e) or severe (f) (scale bar represents 250 μm). g–i Alz-
heimer disease (AD) [148]. The three images show the rounded ame-
boid microglia (g), ramified microglia (h) or foamy macrophages (i) 
that can be seen in AD brains (scale bar represents 10 μm). j–l Mul-
tiple sclerosis (MS) [193]. Three images show variable inflammatory 
activity in MS, with either numerous foamy macrophages within a 
demyelinating plaque (j), macrophages at the rim of a plaque (arrow-
heads) (k), and an inactive plaque with only a few ramified microglia 
(l). All images reproduced with permission
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fatality rate, with survivors experiencing severe neurologi-
cal sequelae and memory deficits that may worsen over time 
[111, 209, 272, 329, 340]. Upon entry into the parenchyma, 
viruses infect and replicate in neurons and/or glia, initiating 
an inflammatory response. The production of various soluble 
factors by resident brain cells recruits a range of leukocytes 
from the periphery, including monocytes and lymphocytes, 
which carry out effector functions necessary for viral clear-
ance [188]. In severe viral encephalitis, large numbers of 
microglia and peripherally-derived MDMs can be seen in 
human post-mortem tissue (Fig. 1a). However, this response 
is not always beneficial and an overexuberant inflammatory 
response may also drive neuropathology [185]. For instance, 
in West Nile virus (WNV) encephalitis, the infiltration of 
MDMs is particularly associated with injury to brain cells, 
tissue swelling and the development of seizures [120–123]. 
In modelling these responses in the CNS, murine models 
inoculated with a relevant neurotropic virus are commonly 
used, although this may not necessarily reflect true disease 
in the human.
Relevance of murine models to human viral 
encephalitis disease
While extensive research has uncovered various processes 
involved in the pathogenesis of viral encephalitis, there are 
significant differences between mouse models and human 
disease. To begin with, researchers use a variety of inocula-
tion routes for the same virus, including intradermal, sub-
cutaneous, intravenous, intramuscular, intracranial or intra-
nasal. These routes of inoculation model different aspects of 
pathology, but vary in invasiveness and viral dose, with very 
few replicating the usual route of infection by the homolo-
gous virus in humans [39, 72, 80, 184, 337]. This has a 
significant impact on (1) local innate and immune defen-
sive responses, (2) spread of virus locally or systemically, 
and (3) presentation of viral antigen in local draining lymph 
nodes versus wide dissemination throughout the animal, all 
of which may substantially alter the outcomes of infection 
[39, 337].
The choice of mouse and virus strain may further 
influence disease pathogenesis and the outcome of infec-
tion. Investigators use different mouse strains, frequently, 
C57BL/6 or BALB/c, for example, which have widely dis-
parate responses to viruses. Genetically modified, usually 
transgenic or knockout animals, are also commonly used, 
which take little account of the compensatory changes that 
may occur in the absence or presence of a particular gene 
and which consequently demonstrate very different immune 
responses to infection [39, 80], with local availability often 
dictating the choice of strain for these studies. It is also com-
mon for different laboratories to use different strains of the 
same virus, often a specifically laboratory-adapted strain, 
often dictated by the availability of the appropriate biosafety 
facilities (e.g., BSL-2 versus BSL-3), or a virus monoga-
mous to the model host, or one that is seldom encountered 
by it [141], potentially compounding this still further. Mice 
are almost always used at an age convenient to the model 
being studied, with weaning, the formation of the BBB, 
puberty and sexual maturity, being common temporal land-
marks for infection [8, 123, 368]. This is often to enable reli-
able infection (e.g., some neurotropic viruses will only infect 
mice prior to the formation of the BBB), but differences 
in immune system maturity can significantly influence the 
immune response to infection. Furthermore, until recently 
in immunological work, it has been common to use only 
female mice, which ignores the effect of sex differences on 
the immune response. Finally, there is increasing awareness 
of the effects of the cellular circadian clock and diet on cel-
lular metabolism driving immune responses [195, 307, 308], 
with differences in housing conditions and significant vari-
ability in macronutrient composition of ad libitum ‘standard’ 
chow between institutions.
Variables of this kind make infallible comparison 
between experimental models difficult, even before consid-
ering their applicability in humans. However, the stochastic 
incidence and clinical presentation of established illness 
and its subsequent chronicity in human disease, often after 
any antecedent pathogenesis can be recorded, the variable 
availability and timing of investigative modalities, access 
to samples, usually restricted to body fluids, occasional 
biopsies and/or post-mortem tissue, with tissue degradation 
due to post-mortem delays often reducing the reliability of 
results, also impose significant limitations on its detailed 
study, ultimately increasing our reliance on experimental 
animal models as an important complementary approach to 
investigating human disease. Needless to say, many of these 
benefits and drawbacks also apply to the study of other neu-
rological diseases.
Microglia in viral encephalitis
Neuroprotective role of microglia in acute‑phase viral 
encephalitis
Historically, using non-selective techniques, microglia were 
argued to have a neurotoxic role in encephalitis, producing 
inflammatory cytokines and orchestrating immune-medi-
ated pathology [53, 263]. With the recent development of 
PLX5622, a colony-stimulating factor 1 receptor (CSF1R) 
inhibitor that causes rapid microglia depletion [295], the 
functions of microglia in viral encephalitis have been 
extensively revised. Despite other CSF1R inhibitors (i.e., 
PLX3397 and BLZ945) being available before PLX5622, 
few studies investigating viral encephalitis utilised these 
earlier compounds. PLX5622 is generally formulated into 
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chow or administered via oral gavage. It enables sustained 
microglial depletion without breaching the BBB, without 
toxicity and without initiating an inflammatory response, 
as seen with other microglial depletion methods [295, 299, 
331]. However, this reagent is not microglia-specific, as 
other cells also express CSF1R [131]. Despite a lack of con-
firmatory evidence [134], it was suggested that PLX5622 
also causes functional impairments in peripheral lymphoid 
and myeloid compartments [198]. This molecule likely also 
affects BAMs, as reported in the case of PLX3397 [317], 
placing an important caveat on the interpretation of data 
where PLX5622 is assumed to be purely microglia-specific.
Microglia ablation in Mouse Hepatitis Virus (MHV), 
Japanese Encephalitis Virus (JEV), Theiler’s Encepha-
lomyelitis Virus (TMEV), Pseudorabies Virus (PRV) 
and WNV encephalitis models has demonstrated a clear 
neuroprotective role of these cells in the acute phase of 
infection [96, 107, 274, 279, 335, 344], and alternative 
microglial depletion methods in Vesicular Stomatitis Virus 
(VSV) infection have produced similar findings [59, 234]. 
In some of these studies, microglial depletion resulted in 
increased weight loss, increased viral burden and persis-
tence, as well as increased viral spread in the CNS and into 
the periphery [96, 107, 335, 344]. A detailed comparison 
of recent work using PLX5622 to deplete microglia in dif-
ferent viral encephalitis models is shown in Tables 1 and 
2. Collectively, these findings suggest that microglia are 
pivotal in controlling virus spread in the CNS, with this 
protective role required especially in the earlier phases of 
disease [96, 107, 335, 344]. Nevertheless, there is sub-
stantial disparity between studies in the elucidation of 
the precise mechanisms by which microglia control viral 
spread, presumably consistent with the divergent evolution 
of virus-host survival strategies for different viral patho-
gens. Figure 2 illustrates the putative pathogenic and pro-
tective roles of microglia and MDM in viral encephalitis.
Table 1  Comparison of studies using PLX5622 to deplete microglia in various models of viral encephalitis (part 1)
















Daniel's strain of 
TMEV
intracranial (i.c) 7 C57BL/6
Males
4 weeks old








footpad (f.p) 14 C57BL/6
Males
6 weeks old
Yes Yes Yes Yes








variant of the 





Yes N/R N/R Yes




intranasal (i.n) Yes N/R N/R N/R
Recombinant 
parental JHMV
i.p Yes N/R N/R N/R
Waltl et al. 
[334]






Yes Yes Yes Yes
Seitz et al. [279] WNV-NY99 f.p 14 Swiss-Webster
Female
7–10 weeks old
Yes N/R No Yes
p3 strain of JEV Yes N/R No Yes







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Microglial role in effective T cell responses mediating viral 
clearance
The importance of an effective T cell response in viral clear-
ance and improved disease outcome has been shown in vari-
ous viral encephalitis models. T cell activation requires anti-
gen presentation and co-stimulation via antigen-presenting 
cell (APC)-expressed Major Histocompatibility Complex 
antigen (MHC) and CD80 (B7-1)/CD86 (B7-2), respec-
tively. Strikingly, in the absence of microglia, several studies 
have shown an ineffective or inadequate  CD8+,  CD4+ T cell 
and/or regulatory T cell (Treg) response, suggesting a role 
for microglia in T cell infiltration and/or activation. How-
ever, many of these studies lack specific evidence and do not 
take into account the indirect effects caused by microglia-
depletion agents.
CD8+ T cells A reduction in the number of APCs in the CNS 
following PLX5622 treatment was thought to contribute to 
a sub-optimal  CD8+ T cell response during WNV infection, 
resulting in poor virus control [107], implicating microglia 
in  CD8+ T cell activation (Table 2). However, in this model, 
both microglia and MDM numbers were reduced in the 
brain, making it difficult to determine whether microglia or 
MDMs were responsible for the reduced T cell activation. 
Paradoxically, numbers of  CD8+ T cells were increased 
in the CNS in microglia-depleted animals compared to 
untreated controls, although these T cells nonetheless dis-
played reduced expression of ‘activation markers’, such as 
CD69 and CD160 [107]. The recent finding that CD69 is a 
marker of CNS-resident T cells [250] further confounds this 
interpretation and more precise analysis will be required to 
determine the contribution of microglia and/or MDMs to 
effective  CD8+ T cell responses in this model.
In addition to decreased APCs in the CNS, the numbers 
of circulating APCs in the spleen, blood, and pancreatico-
duodenal lymph node were also reduced in this model of 
WNV infection [107]. Thus, reduced peripheral APCs could 
also have contributed to a sub-optimal systemic  CD8+ T 
cell response, although other studies using the same dose 
and PLX5622 administration route showed no or limited 
peripheral changes in PLX5622-treated animals (Table 2). 
Differences in the systemic response to PLX5622 may addi-
tionally be due to the age, sex and infection status of mice, or 
the duration of PLX5622 treatment. Thus, interpretation of 
studies using PLX5622 to determine the specific functions 
of microglia must take into account any indirect effects it 
may cause.
Using alternative experimental systems, including fate-
mapping and intravital imaging, Moseman et  al. [234] 
clearly identified a role for microglia in  CD8+ T cell activa-
tion. Microglia were required for the cross-presentation of 
viral antigen from VSV-infected neurons to  CD8+ T cells 
to contain virus and prevent its fatal spread.  CD8+ T cell 
recognition of MHC class I (MHC-I) on microglia was cru-
cial for survival, while conditional deletion experiments in 
this model showed that neuronal MHC-I was not required 
(Fig. 2) [234].
CD4+ T cells Other studies showed a more important role 
for microglia in  CD4+ T cell responses. In TMEV infection, 
PLX5622-driven microglial depletion resulted in reduced 
CNS infiltration of  CD4+  T and  CD44+  CD4+ T cells 
[335], whereas in MHV-infected brains, microglia depletion 
Fig. 2  Protective and pathogenic roles of monocytes and microglia 
in viral encephalitis. a Protective functions. In viral encephalitis, 
microglia enhance viral clearance by phagocytosing virus-infected 
cells. Both microglia and MDMs stimulate anti-viral T cell responses, 
which is optimized by microglia-mediated regulation of Treg infiltra-
tion. b Pathogenic functions. NO- and IL-6-producing MDMs exac-
erbate neuronal damage and contribute to immunopathology. MDM, 
monocyte-derived macrophage; MHC, major histocompatibility com-
plex; NO nitric oxide; IL interleukin; Treg regulatory T cell
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reduced  CD4+ and virus-specific, IFN-γ-expressing  CD4+ T 
cells [344] (Table 2). In the latter study, the authors argued 
that the ineffective  CD4+ T cell response was dependent 
on reduced microglia/macrophage MHC-II expression and 
immaturity of infiltrating APC, collectively preventing re-
stimulation of  CD4+ T cells in the CNS (Fig. 2).
T regulatory cells Increased Treg numbers in the CNS 
resulting from the absence of microglia were also reported in 
two independent viral encephalitis models (Table 2). Tregs 
possess several anti-inflammatory mechanisms, including 
release of interleukin (IL)-10, which dampen the anti-viral 
immune response and reduce immune-mediated pathology 
[151]. Thus, their increased infiltration can hamper effec-
tive viral clearance. Accordingly, the increased number and 
percentage of Tregs in the CNS and increased Il10 mRNA 
expression in TMEV-infected, PLX5622 microglia-depleted 
mice suggest a role for microglia in regulating the infiltra-
tion of Tregs into the brain [335]. In this study, increased 
Treg numbers were thought to contribute to an ineffective 
cytotoxic  CD8+ T cell response, resulting in decreased viral 
control and reduced survival in the absence of microglia. 
Importantly, however, the increase in Treg numbers in this 
study was not statistically different from the non-depleted, 
infected control mice. Furthermore, while this study con-
cluded that Treg numbers affected the  CD8+ T cell response, 
there was a significant increase in IFN-γ in the CNS and 
no change in the number of infiltrating  CD8+ T cells in 
PLX5622-treated animals, suggesting changes in Treg num-
bers did not affect a functional T cell response.
Thus, while discrepancies between studies investigating 
T cell number and their activation in the CNS may sug-
gest a role for microglia in encephalitis caused by particular 
viruses, many of these studies lack specific evidence for the 
contribution of microglia to  CD4+,  CD8+ or Treg responses. 
Moreover, the wider effects of PLX5622 on the myeloid and 
lymphoid compartments [198] make it impossible to assess 
the specific role of microglia using this molecule alone.
The role of microglia in MDM maturation and CNS 
infiltration
The absence of microglia in virus-infected brains also affects 
the number of MDM infiltrating into the CNS, suggesting 
a role for microglia in the recruitment of monocytes from 
the blood. This phenomenon may be virus-specific, as stud-
ies have reported an increase [344], decrease [96, 107] or 
no change [335] in the number of immigrating MDMs in 
these diseases (Table 2). Two studies reporting a differential 
infiltration of MDMs into the virus-infected CNS reported 
a reduction in the expression of MHC-II or CD86 on these 
cells (Table 2), arguably supporting a role for microglia in 
enhancing MDM antigen presentation upon CNS entry. 
However, the possibility that reduced MDM infiltration 
is a result of PLX5622 targeting CSF1R, which is highly 
expressed by these cells, is difficult to exclude.
Despite various groups showing reduced numbers of infil-
trating MDMs and cytokine production in the CNS of micro-
glia-depleted mice during infection, these animals were 
still highly susceptible to lethal encephalitis. This appears 
inconsistent with the observation that inhibiting monocyte 
infiltration into the WNV-infected brain reduces immune-
mediated pathology and enhances survival [120, 122], while 
in contrast, reduced MDM infiltration and decreased Nos2, 
Ifng and Tnf expression in the brains of microglia-depleted 
WNV-infected mice did not improve survival [107]. These 
findings suggest that maintaining a microglial network for 
early defence is as important as reducing subsequent MDM-
mediated immunopathology in viral encephalitis.
The role of microglial migration and phagocytosis in virus 
control
The purinergic receptor, P2RY12, was shown to have a role 
in the control of viral spread in encephalitis caused by PRV, 
an alphaherpesvirus that infects the brain via retrograde syn-
aptic spread from peripheral neurons [96]. Using advanced 
imaging techniques in P2RY12-deficient (P2RY12−/−) mice 
treated with PLX5622 and infected with PRV, this study 
showed rapid, precise microglial migration to and phago-
cytosis of virus-infected neurons to reduce CNS spread 
(Table 2). Microglia/macrophage-mediated engulfment of 
virus-infected neurons has also been observed in human 
WNV-infected brains [247] (Fig. 1a). In PRV infection, this 
process involved microglial migration towards ATP (the 
ligand for P2RY12) released by infected neurons prior to 
the appearance of mature virions in the neuronal cytoplasm 
and before neuronal membranes were compromised. In stark 
contrast to the transcriptional changes seen in neurodegen-
erative diseases [174, 179, 191, 214], microglia upregulated 
P2RY12 by two-fold in this model, demonstrating its impor-
tance in CNS infection.
Similarly, during infection with neurotropic VSV, micro-
glia accumulated in the olfactory bulb, forming an ‘innate 
barrier’ which impeded viral spread to caudal regions of the 
brain [59]. Consequently, microglial depletion with BLZ945, 
a different CSF1R inhibitor, resulted in increased VSV load 
and spread, transforming a sublethal infection into lethal 
encephalitis. Here, microglial ‘activation’ and accumulation 
relied on neuron–astrocyte crosstalk. Abrogation of IFN-
α/β receptor in neurons and astrocytes, but not microglia, 
resulted in reduced microglial activation, accumulation, pro-
liferation and enhanced viral spread and mortality. This sug-
gests that IFN-β produced in the olfactory bulbs stimulates 
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IFN-α/β receptor signaling in neurons and astrocytes, indi-
rectly enhancing the microglial anti-viral response.
Role of aberrant synaptic pruning in post‑viral cognitive 
dysfunction
Patients recovering from viral encephalitis often show 
severe neurological sequelae, including deficits in memory, 
visuospatial and verbal learning, and motor and executive 
functions [111, 209, 272, 329, 340]. Permanent cognitive 
dysfunction after infectious encephalitis can occur without 
neuroinvasion, with cognitive deficits worsening over time 
[237]. In WNV and Zika virus (ZIKV) encephalitis, micro-
glia have been identified as orchestrators of spatial-learning 
impairments seen in the recovery phase after viral neuroin-
vasion [111, 324].
While the phagocytic role of microglia may be protec-
tive in the acute phase of viral infection, the same function 
can become detrimental post infection. This is shown by the 
inappropriate removal of hippocampal synapses leading to 
circuitry dysfunction and spatial-learning deficits in the clin-
ical recovery phase from WNV and ZIKV neuroinvasive dis-
ease [111, 324]. Both studies show the importance of com-
plement protein C3, the hydrolysed fragment of which, C3a, 
is recognized by microglial-expressed C3a receptor (C3aR), 
in the aberrant engulfment of synapses. Discrete immuno-
pathological effects post infection with different flaviviruses 
were demonstrated by Gaber et al. [109], with WNV infec-
tion associated with the enhanced elimination of presynaptic 
termini and ZIKV infection resulting in neuronal cell death 
and the enhanced elimination of post-synaptic termini. This 
study elegantly showed that the persistence of  CD8+ T cells 
expressing IFN-γ in the brain parenchyma was required 
for both microglial activation and the neuronal loss and/or 
synapse elimination resulting in cognitive dysfunction dur-
ing the recovery from WNV and ZIKV infection. Accord-
ingly, absence of microglial Ifngr prevented the effects of 
flavivirus-induced hippocampal damage and related clinical 
deficits [111].
Nonetheless, enhanced microglia-mediated synaptic 
engulfment during insult, infection or injury may well be 
a protective mechanism, for instance by preventing excito-
toxicity and dampening nonsense signalling activity from 
damaged or injured neurons [342] or, in the context of neu-
rotropic infection, by limiting trans-synaptic viral spread or 
aberrant calcium signalling by infected neurons [324]. At 
the same time, this can also lead to the collateral loss of 
bystander synapses, a process also observed in CNS patholo-
gies, such as Alzheimer’s Disease (AD) and related demen-
tias [62, 104], and in animal models of Multiple Sclerosis 
(MS) [10, 21]. While this remains a matter of debate, it has 
been proposed that C3aR-dependent microglial synaptic 
engulfment has a role in the functional decline observed in 
MS [342], AD [152] and aging (Fig. 4). Much like in WNV 
infection, synapse elimination occurs predominantly at the 
presynaptic termini and is dependent on the alternative com-
plement cascade (i.e., C3 hydrolysis). Similarly, impaired 
learning coinciding with synapse and neuronal loss was 
abolished in aged mice deficient in C3 [285]. Furthermore, 
IFN-γ-induced C3 expression in an amyloidogenic mouse 
model reduced plaque load but resulted in increased loss 
of synapses and cognitive dysfunction [152, 284]. Thus, in 
various CNS diseases, microglia show conserved pathologi-
cal mechanisms, which could be targeted for the modulation 
of disease processes.
Monocytes in viral encephalitis
The severe neuroinflammatory response associated with 
viral encephalitis recruits a substantial monocytic infil-
trate from the periphery, constituting more than 50% of all 
recruited cells in some disease models [122, 123]. This sig-
nificant infiltration is also evident in severe viral encephalitis 
in humans at postmortem [11, 247, 273] (Fig. 1a). Together 
with recruited lymphocytes and resident microglia, mono-
cytes carry out inflammatory and anti-viral effector functions 
necessary for viral clearance [188]. However, this response 
is not always beneficial and an overexuberant inflammatory 
response may contribute to fatal encephalitis. A comparison 
of the differential roles and associated phenotypes (RNA and 
protein) of microglia compared to MCs in viral encephalitis 
can be seen in Table 3.
Monocyte‑mediated viral clearance contributes 
to secondary tissue damage
Upon entry into the infected brain, MDMs can present viral 
antigen and support  CD4+ T cell-mediated viral clearance 
or contribute to the killing of infected cells through release 
of inflammatory mediators, such as NO and IL-6 [16, 22, 54, 
200] (Fig. 2). While these responses enhance pathogen clear-
ance, they can also contribute to substantial neurodegenera-
tion [70, 120, 122, 123, 155, 334]. During WNV infection 
in the mouse, for instance, the infiltration of  Ly6Chi mono-
cytes into the infected brain coincides with the onset of fatal 
encephalitis [122, 123]. These inflammatory monocytes are 
recruited to the CNS in a C–C Motif Chemokine Ligand 2 
(CCL2)- and very late antigen-4 (VLA-4)-dependent man-
ner and exacerbate CNS injury through sustained produc-
tion of NO [122, 123]. Inhibiting monocyte infiltration into 
the brain with anti-CCL2 and anti-VLA-4 antibody block-
ade or inhibiting their inflammatory activation by inhibi-
tion of Nos2 with aminoguanidine hemisulphate signifi-
cantly increases survival in infected mice without altering 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































monocytes and MDMs mediate inflammatory damage in 
WNV infection.
The detrimental role of monocytes in the context of 
viral encephalitis is likely confined to the CNS paren-
chyma [122], as these cells play an essential and benefi-
cial role in controlling WNV infection in the periphery 
prior to their infiltration into the CNS [73], although they 
also contribute to significant local tissue damage in the 
periphery in alphavirus infection [363]. This is consistent 
with studies showing that the reduction of monocytes into 
the CNS using CCR2-, CCL2-, and CCL7-deficient mice 
or in vivo clodronate liposome administration increased 
viral burden when virus was peripherally inoculated [16, 
22, 200]. Upon entry into the infected brain, monocytes 
express MHC-II, CD80 and CD86 and have the capacity 
to present antigen and stimulate the proliferation of acti-
vated T cells [122] (Fig. 2), together supporting their role 
in inducing anti-viral T cell responses. It is possible that 
a detrimental or beneficial response of monocyte-derived 
cells in WNV encephalitis depends on the virus strain, 
dose, and route of inoculation. However, considering their 
relatively late arrival into the CNS parenchyma [122], 
whether these cells contribute to WNV clearance in the 
brain is still unclear.
Potential role of monocytes in seizure development
The recruitment of monocytes into the CNS following 
infection with TMEV is also thought to significantly con-
tribute to hippocampal neurodegeneration [155] and sei-
zure development during viral encephalitis [70, 334]. This 
pathological role is emphasized by studies demonstrating 
that the in vivo depletion of myeloid cells with anti-Gr-1 
antibody or with anti-inflammatory agents, wogonin and 
minocycline, preserved cognitive functions and reduced 
seizure incidence [70, 155, 334]. Although these studies 
attributed ameliorated disease signs to reduced monocyte 
trafficking into the brain, the findings are potentially con-
founded by non-specific depletion methods; thus, the par-
ticipation of other cell types cannot be excluded. Using 
a different monocyte-depletion method with clodronate 
liposomes (which deplete phagocytes in the blood-
stream, spleen, and BM [319–321]), seizure severity was 
improved but there was no amelioration in hippocampal 
neurodegeneration [334], suggesting the observed con-
tribution of monocytes to pathology is dependent on the 
depletion method. Altogether, whether seizures originate 
innately in embryologically primed, infected neurons or 
exogenously from parenchymal or other infiltrating cell 
stimuli remains unclear [70, 120, 122, 123, 155, 334] and 















































































































































































































































































































































































































encephalitis-induced seizures will require more precise 
investigation.
Ischemic injury and repair
Stroke, which can be generally divided into haemorrhagic 
stroke and ischemic stroke, accounts for approximately 
10% of all deaths and 5% of all disability-adjusted life 
years worldwide [239]. Ischemic strokes are the most prev-
alent type of stroke [176], and they are caused by arterial 
occlusion, which is most commonly caused by large ves-
sel atherosclerosis and plaque rupture, cardioembolism, 
and small vessel disease (typically linked to hypertension) 
[176, 330]. In general, however, ischemic stroke is a clini-
cally heterogeneous condition determined by the degree, 
duration, and location of ischemia, as well as age, sex, and 
multi-medication comorbidities [290]. Although rodent 
models may reproduce the consequences of an ischemic 
insult, they often fail to recreate the complex pathophysi-
ology that leads to an endogenous stroke [208].
Relevance of murine models to human ischemic 
stroke
Animal models of ischemic stroke carry significant limita-
tions in replicating the aetiology and time course of human 
disease. Many researchers have attempted to model dis-
ease pathogenesis in young, healthy male rodents [51, 83, 
208], despite the fact that ischemic stroke is most preva-
lent in older individuals [24, 95] and is strongly linked 
to systemic diseases, such as hypertension, hypercholes-
terolemia, obesity, and diabetes mellitus [14]. With the 
exception of thromboembolic clot models [290], these 
models also fail to replicate the delayed spontaneous 
reperfusion reported in 17% of human thromboembolic 
strokes [175]. While the sequence of events following 
cerebral ischemia is similar in humans and rodents, the 
kinetics of this response also vary substantially [154]. This 
impacts the therapeutic window for reversible ischemic 
damage [154], as well as the functional recovery period, 
which can span years in humans [47]. These discrepancies 
between stroke animal research and clinical practice have 
been identified as a leading cause of translational failures 
[28, 158], prompting significant reform in study design 
and experimental model selection in the field [33, 100, 
157, 207].
These limitations have recently been addressed by 
either inducing stroke in aged animals with pre-existing 
comorbidities (e.g., diabetes, hyperlipidemia, obesity, 
infection), reviewed in [217], or using animal models with 
risk factors that eventually result in spontaneous stroke 
(e.g., spontaneous hypertensive rat and stroke-prone spon-
taneously hypertensive rat) [92, 245]. Although these 
models more accurately mimic human ischemic stroke 
[290], they nonetheless recreate only individual aspects 
of this clinically heterogeneous disease [208]. Therefore, 
investigations attempting to generalize findings from iso-
lated experimental models of ischemic stroke should be 
interpreted with extreme caution.
Nonetheless, animal models have been invaluable in 
understanding evolving brain injury following an ischemic 
insult [84]. Within minutes of blood flow interruption 
(15–20% below baseline), irreversible cell death ensues, 
resulting in the formation of an infarct core [85]. The 
penumbra, or non-functional tissue around the infarct core, 
may recover; however, if blood flow is not restored, this "at-
risk" tissue will be incorporated into the infarct core [13, 
305]. Infarcts often continue to expand even after blood 
flow is restored to the occluded region, in the process of 
ischemia–reperfusion injury [244].
The sequence of events following an ischemic injury 
and involvement of resident and peripheral immune cells is 
remarkably similar between human disease and its experi-
mental models. Examination of post-mortem human stroke 
lesions demonstrates that inflammation begins early after 
ischemic insult [223] and the surrounding penumbral tis-
sue is rapidly surrounded by ‘activated’ microglia [90]. This 
inflammatory response is associated with the release of dam-
age-associated molecular patterns (DAMPs) from injured 
neurons, BBB breakdown, and infiltration of peripheral 
immune cells, including monocytes and neutrophils, into the 
ipsilateral hemisphere [90], with macrophages, mononuclear 
cells, and perivascular cuffing present in 75%, 44%, and 42% 
of human brains with ischemic infarcts, respectively [223]. 
Although infiltrating immune cells may act in concert with 
resident cells to initiate debris clearance and tissue repair 
processes [369], acute inflammation may persist and trans-
form into chronic, non-resolving inflammation. Inflamma-
tory mononuclear cells and macrophages may persist for 
up to 53 years following the initial ischemic insult [223] 
and are often present in chronic lesions (Fig. 1b). Aber-
rant acute inflammation may also contribute to secondary 
injury, aggravating tissue damage and increasing lesion vol-
ume [160]. As a result, the neuroinflammatory response to 
ischemic injury is a critical determinant of brain damage and 
neurological recovery following a stroke. Despite variations 
in the kinetics the inflammatory response underlying this 
process [171], animal models show cross-species parallels 




Microglial modulation of dysfunctional CNS cellular 
responses in stroke
The roles of microglia in the early stages of ischemic injury 
have been largely elucidated by experimental models of 
ischemic stroke induced by middle cerebral artery occlu-
sion (MCAO), which generates reproducible infarcts in the 
middle cerebral artery region and allows reperfusion after 
removal of the occluding filament (i.e., transient MCAO). 
Although blood flow restoration in transient MCAO does not 
accurately depict spontaneous reperfusion in human stroke, 
it is a better representation of mechanical thrombectomy or 
thrombolysis in the human than endogenous stroke [208]. In 
models of transient or permanent cerebral ischemia induced 
by MCAO, microglial depletion increased infarct size and 
worsened disease outcome, suggesting that microglia play 
a beneficial role in the early phases of stroke. Studies have 
suggested that this protective role may include direct cell 
interactions with surrounding parenchymal cells, resulting 
in the containment and/or prevention of dysregulated neuron 
[117], neutrophil [248] and astrocyte [172] responses that 
occur following ischemic insult (Fig. 3).
Experimental microglia depletion in animals has pro-
vided insight into the immune processes that protect against 
secondary injury, which may also underlie human disease. 
Two MCAO studies found an increase in neuronal death 
and infarct size after microglia were depleted by continu-
ous oral injection of PLX3397 starting three weeks before 
stroke induction [117, 172] (Table 4). Increased tissue dam-
age was linked to increased intraneural calcium levels and 
excitotoxic injury in one study, suggesting that microglia 
may play a role in protecting neurons from injury associated 
Fig. 3  Roles of monocytes and 
microglia in ischemic stroke. 
In stroke, microglia migrate 
towards neurons with high 
intracellular calcium levels 
to reduce excitotoxicity and 
neuronal damage. Microglia 
also prevent bystander tissue 
damage by inhibiting reactive 
astrocytes and phagocytos-
ing infiltrating neutrophils. 
 CXCR4+ MDM are recruited 
to the site of injury, where they 
produce microglia-activating 
mediators, IL-1β and ROS, and 
stimulate microglia proliferation 
and the glial scar formation. 
These inflammatory mediators 
may also injure neurons and 
contribute to secondary dam-
age. CNS-infiltrating  Ly6Chi 
monocytes may also help repair 
the damaged BBB via the 
production of collagen-4 and 
TGF-β1. BBB, blood–brain bar-
rier; CXCR4, CXC chemokine 
receptor type 4; CXCL12, 
CXC Motif Chemokine Ligand 
12; IL, interleukin; MDM, 
monocyte-derived macrophage; 
ROS, reactive oxygen species; 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































with high intracellular calcium levels [117] (Fig. 3). Impor-
tantly, the increased infarct damage did not occur if micro-
glia were allowed to repopulate by removal of PLX3397 
before stroke induction, thus emphasising their protective 
role in stroke. Microglia rapidly migrated to infarct sites and 
formed contact interactions with neurons with high intracel-
lular calcium levels, likely reducing excitotoxic damage. At 
the interface between microglia and neurons, the purinergic 
receptor P2RY12 was highly expressed. P2RY12 is consid-
ered a homeostatic microglia marker because of its down-
regulation in neurogenerative and neuroinflammatory mod-
els, including amyotrophic lateral sclerosis, AD (Table 5) 
and MS (Table 6) [174, 179, 191, 214], which have been 
more extensively investigated than encephalitis (Table 3) 
and stroke (Table 4). Considering P2RY12 is upregulated 
by microglia in stroke [117] and is required for the control 
of viral spread in PRV encephalitis [96], it may not be a 
general homeostatic microglia marker as currently proposed. 
The transcriptomes and proteomes of microglia and MC in 
viral encephalitis, stroke, AD and MS are listed in Tables 3, 
4, 5, 6, respectively.  
In a different MCAO study, enhanced brain injury in the 
absence of microglia was associated with an increased pro-
duction of pro-inflammatory mediators by astrocytes (IL-1α, 
Table 5  Functions and phenotypes of microglia in Alzheimer's disease
a Single molecule fluorescence in situ hybridization
RNA Three microglia phenotypes. All express: Hexb and Cst3
‘Homeostatic’ phenotype: Cx3cr1, P2ry12, Tmem119, Hexb, Cst3, Cx3cr1, Ctsd, Csf1r, Ctss, Sparc, Tmsb4x, P2ry12, P2ry13, 
C1qa and C1qb
TREM-2-independent, ‘intermediate state’ microglia phenotype:
↑ Tyrobp, Apoe, B2m, Ctsd, Ctsb, Fth1 and Lyz2
↓Cx3cr1, P2ry12, P2ry13 and Tmem119
TREM-2 dependent, damage-associated microglia (DAM) phenotype:
↑↑ Tyrobp, Apoe, B2m, Ctsd, Ctsb, Fth1 and Lyz2
↑Cst7, Lpl, Trem2, Axl, Cstsl, Cd9, Csf1, Ccl6, Itgax, Clec7a, Lilrb4 and Timp2
↓↓ Cx3cr1, P2ry12, P2ry13 and Tmem119
(5xFAD at 3 and 8 months, single-cell RNA-seq [179])
Microglia neurodegenerative phenotype (MGnD)
↓↓ P2ry12, Tmem119, Gpr34, Jun, Olfml3, Csf1r, Hexb, Mertk, Rhob, Cx3cr1, Tgfbr1, Tgfb1, Mef2a, Mafb, Jun, Sall1 and Egr1 
(‘homeostatic’ genes)
↑ Spp1, Itgax, Axl, Lilrb4, Clec7a, Ccl2, Csf1 and Apoe (‘inflammatory’ genes)
(APP-PS1 at 7, 10 and 17 months. MGnD is also seen in ALS  (SOD1G93A mice) and in MS (acute EAE), single-cell RNA-seq 
[191])
Protein Three microglia phenotypes:
Phenotype 1:  Clec7a−P2ry12+ (not associated with Aβ plaques)
Phenotype 2:  Clec7aloP2ry12lo (in close proximity to Aβ plaques)
Phenotype 3:  Clec7a+P2ry12–
Transition from  Clec7a− to  Clec7aint to  Clec7ahi correlated with increased mRNA expression of Apoe and suppression of homeo-
static molecules
(APP-PS1, immunohistochemistry [191])




(APP-PS1, flow cytometry [191])
Iba-1+CD11c+TIMP2+ microglia
Co-localized with Aβ+, Csf1 and Lpl




Microglia encircle Aβ plaques to prevent further growth and dissemination into the parenchyma [63], reducing damage to local 
neurites [295]
Microglia may contribute to the phagocytic and enzymatic clearance of the Aβ plaque deposits [82]
TREM2 expressed by damage-associated microglia is thought to directly recognise Aβ to enhance engulfment and lysosomal deg-
radation of the protein [338, 357, 366]
TREM2-dependent microglia functions are required to prevent seeding of plaques earlier in AD, whilst later on enhance the con-




Microglia cause synapse and neuronal damage, injury, or loss, resulting in memory loss and cognitive decline [152, 284, 291, 
294–296]
Microglia contribute to the formation and growth of Aβ plaques [294, 295]



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































IL-1β, iNOS, IL-6 and TNF), implicating a role for microglia 
in inhibiting dysfunctional astrocyte responses [172] (Fig. 3 
and Table 4). Moreover, after PLX3397-mediated micro-
glia depletion, MCAO in either Rag2–/–γc–/– mice (which 
lack T, B, Natural Killer and Natural Killer T cells), or in 
mice treated with Bindarit (which inhibits CCL2-mediated 
monocyte infiltration) resulted in enhanced infarct injury 
compared to mice without PLX3397, emphasizing that the 
absence of microglia, rather than the presence of a particular 
infiltrating immune cell type, exacerbates brain injury [172].
Besides the described protective interactions with astro-
cytes and neurons, microglia also exert beneficial func-
tions in the brain by phagocytosing infiltrating neutrophils, 
thereby preventing their pathogenic accumulation and sub-
sequent damage to the surrounding tissues and vasculature 
[248]. Indeed, inhibition or genetic deletion of neutrophil 
elastase, blocking neutrophil recruitment and/or infiltra-
tion, or inhibiting neutrophil-derived matrix metallopro-
teinase-9, all reduce lesion progression [170, 218, 248, 
301]. Accordingly, depletion of microglia before stroke 
induction increased neutrophil numbers in the CNS and 
exacerbated tissue damage [248]. Thus, microglia cru-
cially minimise pathogenic neutrophil accumulation to 
limit ongoing secondary oxidative damage of surround-
ing re-perfused vasculature and brain tissue [248] (Fig. 3 
and Table 4).
However, the beneficial roles played by microglia after 
ischemic stroke are mostly based on studies in young mice, 
which do not reflect changes in the aging immune system 
that would occur in the majority of stroke patients. Stud-
ies investigating these age-related changes in the immune 
responses to MCAO have demonstrated that, although older 
and young mice have a similar inflammatory response pro-
file, the magnitude of this response differs considerably [9]. 
Given that aging microglia exhibit greater inflammatory 
alterations [292], it is possible that these cells carry out del-
eterious immune responses following ischemic injury that 
are not evident in young animals.
Pathogenic role of microglia in the context of diabetes 
co‑morbidity
Importantly, approximately 70% of stroke patients have 
pre-existing conditions, such as diabetes and high blood 
pressure, with diabetes being associated with significantly 
worsened recovery and post-stroke cognitive impairment 
[168, 315]. To study the link between microglia, stroke, 
and diabetes, Jackson et al. [168] used an intracerebroven-
tricular injection of short hairpin RNA to silence Csfr1 and 
ablate microglia prior to the induction of stroke via transient 
MCAO in young mice with diet and streptozotocin-induced 
type 2 diabetes mellitus [168]. It is known that an increased 
ratio of pro- to anti-inflammatory microglia in diabetic 
animals correlates with the development of post-stroke cog-
nitive impairment [167]. In contrast to studies in mice with-
out comorbidities, microglial depletion in diabetic animals 
decreased ischemia-mediated brain injury (Table 4), indi-
cating a diminished protective role of microglia in diabetes 
[168]. This study emphasizes the importance of pre-existing 
co-morbidities in both understanding the role of microglia in 
stroke pathology and the potential translation of microglia-
targeted treatments for this disease. Microglia studies in 
older mice with diabetes or other systemic cerebrovascular 
illnesses, such as hypertension or atherosclerosis, are criti-
cal for translating these findings to clinical practice, as the 
majority of ischemic strokes occur in older individuals [24, 
95] with underlying cerebrovascular disease [14].
Monocytes in stroke
Monocyte contribution to tissue damage and repair
The immune response to ischemic injury critically involves 
the infiltration of peripheral immune cells, including mono-
cytes and neutrophils [116, 171]. Monocyte activation has a 
significant impact on disease outcome following CNS injury, 
in particular, the secondary damage following ischemic 
stroke. The differential protective or pathogenic roles of 
monocytes in experimental models of ischemic stroke, as 
well as their associated phenotypes, are compared in Table 4.
In response to ischemic injury, infiltrating monocytes 
may adopt functional phenotypes facilitating debris clear-
ance, wound healing, and tissue repair (i.e., pro-resolution 
phenotypes) [360]. However, these cells may also adopt a 
pro-inflammatory phenotype whose sustained production 
of inflammatory mediators risks secondary damage to sur-
viving tissue. Following ischemic injury and haemorrhagic 
stroke, for instance, monocytes recruited to the injured 
brain cause inflammatory damage and functional impair-
ment via their sustained production of TNF and IL-1β [81, 
143, 192, 269]. The pathological role of these cells is further 
emphasized by studies in CCR2-deficient mice in which the 
reduced monocyte influx into the injured brain substantially 
reduces inflammation and secondary damage [81, 192]. 
However, the same cells subsequently contribute to tissue 
repair. In CCR2-deficient mice or following early mono-
cyte depletion by clodronate liposomes in stroke, the result-
ant reduced expression of tissue repair proteins, including 
TGF-β1 and collagen-4, was associated with neurovascular 
unit instability and later haemorrhagic transformation [127], 
demonstrating the importance of these cells in healing after 
stroke.
Thus, although a pro-inflammatory monocyte pheno-
type is thought to contribute to secondary damage, this 
functional specification can also activate immune system 
processes involved in wound healing and tissue repair 
Acta Neuropathologica 
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[360]. This may involve other cell types. For instance, 
microglial activation and proliferation is necessary in 
the formation of a glial scar around injured tissue [271]. 
Using two experimental models of ischemic stroke (pho-
tothrombosis and transient MCAO), it was recently sug-
gested that monocytes expressing inflammatory mediators 
IL-1β and Cybb-derived reactive oxygen species (ROS) 
facilitated microglial proliferation and enhanced wound 
healing [343]. This damaging phenotype was, however 
tightly regulated. Following their initial pro-inflammatory 
activity, monocytes were physically enclosed in a glial scar 
facilitated by chemotactic CXCR4-CXCL12 signalling, 
thereby limiting monocyte-driven secondary injury [343]. 
Notably, the tissue infiltration patterns of monocytes and 
microglia differed among stroke models, potentially sug-
gesting that multiple experimental models are necessary to 
fully comprehend the activities of these two cell types in 
disease. Nonetheless, the beneficial outcome of myeloid-
mediated inflammation in these ischemic stroke models 
contrasts with that of experimental models of MS or viral 
encephalitis, where a sustained oxidative stress phenotype 
is detrimental [122, 224], and points towards the impor-
tance of local regulatory mechanisms in preventing aber-
rant inflammatory damage.
The seemingly paradoxical protective and pathogenic 
functions of monocytes may be further explained by the 
recruitment of multiple populations that differentially con-
tribute to damage and repair as monocytes. Such populations 
may be differentially recruited to the site of ischemic injury 
in a manner similar to that occurring in mechanical injury: 
following mechanical spinal cord injury, ‘protective’ pro-
resolution monocytes  (Ly6CloCX3CR1hi) were thought to 
gain access to the CNS from the choroid plexus and migrate 
to the injured spinal cord parenchyma through the central 
canal, whereas detrimental pro-inflammatory monocytes 
 (Ly6ChiCCR2+) were proposed to transmigrate via the spi-
nal cord leptomeninges in a CCL2-dependent manner [281]. 
The differential expression of Ly6C may underlie these dif-
ferences, as high expression of Ly6C would better enable the 
emigration of inflammatory cells from the CNS leptomenin-
geal vasculature [310]. CNS region-specific signals may also 
shape their eventual functions within the CNS, with those 
trafficking through the choroid plexus and cerebrospinal 
fluid encountering stimuli that shape more anti-inflamma-
tory roles [281]. Whether these CNS environments shape 
distinct cellular functions of infiltrating cells following 
stroke warrants further investigation. Indeed, in other disease 
models such as EAE, it is evident that the cytokine milieu 
in the choroid plexus shapes the pro- or anti-inflammatory 
specification of infiltrating monocytes [164].
It is crucial to remember that inflammation can be both 
harmful and beneficial to recovery from ischemic injury, 
and that any therapeutic window may be limited to a specific 
time period when inflammation is pathogenic. Although this 
therapeutic window is well-defined experimentally [171], 
the time course of lesion evolution is protracted in humans 
and complicated by recurrent ischemic episodes and sys-
temic co-morbidities [223]. The roles, phenotypes, and tran-
scriptomic profiles of both microglia and monocytes in ani-
mal models that better re-create the disease co-morbidities 
that lead to, and modulate the immune response to, ischemic 
stroke are therefore critically needed.
Neurodegeneration
Alzheimer’s disease is a chronic neurodegenerative disease 
causing progressive and irreversible cognitive decline. 
Disease onset can occur at < 65 (familial early-onset) 
or > 65 years of age (sporadic late-onset), with the latter 
afflicting more than 95% of patients [87, 213]. Histopatho-
logically, AD is characterized by the formation of intra-
neuronal neurofibrillary tangles consisting of the hyper-
phosphorylated microtubule protein, tau, and extracellular 
deposits of plaques of amyloid-β (Aβ), a breakdown prod-
uct of the transmembrane amyloid precursor protein (APP) 
[241]. A transgenic system that reproduces either of these 
two characteristic AD pathologies is the most common 
approach to modelling AD in mice. In transgenic mouse 
models, Aβ plaques are generally generated by mice over-
expressing five human familial AD gene mutations (i.e., 
5xFAD mice) or the APP-presenilin 1 gene (i.e., APP-
PS1 mice) [142]. Tauopathy is generally modelled in mice 
over-expressing human transgenic tau. However, these ani-
mal models do not reflect the entire biology of human AD, 
which presents inherent limitations to the translation of 
laboratory findings into a clinically relevant setting.
Relevance of murine models to human AD
Modelling all aspects of AD pathology in an experimental 
animal setting is difficult. This can be attributed in part to 
(1) the disease being unique to humans, as far as we know, 
(2) the multifactorial nature of AD having both genetic 
and environmental etiologies, and (3) the high variabil-
ity in disease onset, development and progression among 
patients [86].
Currently, transgenic mouse lines are the most common 
experimental model for AD, despite each only recapitu-
lating one or few aspects of the human pathology. These 
transgenic mice express human genes that result in the 
formation of amyloid plaques (APP or PSEN1) and/or neu-
rofibrillary tangles (MAPT), with other aspects of human 
pathology incompletely represented, such as memory-
associated cognitive impairments, contribution of aging, 
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neuronal loss, widespread neurodegeneration and regional 
brain atrophy [86, 325]. It is thus little wonder that the 
success rate of drugs that have gone through clinical tri-
als from 2002 to 2012 show a high failure rate (~ 99.6%) 
[69]. In 2020, there was  ~ 40-fold and ~ threefold decrease, 
respectively, in the number of drugs in development for 
AD, compared to those in development for malignant neo-
plasms and diabetes [68]. The high failure rate of agents 
in clinical trials and relatively limited drug development 
for AD reflect the biological disconnect and thus restricted 
translatability between mouse models and human pathol-
ogy. This is further exacerbated by the limited avail-
ability of human biomarkers, longer trial durations and 
prohibitively high trial costs [68, 86, 102]. Also feeding 
into this is the fact that mouse models are largely based 
on the expression of mutations associated with familial 
early-onset AD, while drugs tested in clinical trials are 
mainly in patients with sporadic late-onset form of AD. 
It follows that conclusions based on the interpretation of, 
and extrapolation from mouse findings should be carefully 
contextualized and made with caution. However, impor-
tantly, notwithstanding their limitations, mouse models 
have provided substantial insight into the contribution of 
specific features (i.e., amyloid or tau) in the pathogenesis 
of AD. Thus, understanding the precise limitations of each 
model is necessary to better translate laboratory findings 
into clinically relevant settings.
However, with the increasing incidence of AD and with 
it the increased estimated global expenditure needed for AD 
care, there is an urgent need to develop models that better 
reflect the human disease and inform effective preventive 
and interventive treatment [258]. Improved models of AD 
are underway. These include the use of primates [276], brain 
organoids [249] and further transgenic mouse lines. To sup-
port this, the National Institutes of Health established the 
Model Organism Development & Evaluation for Late-Onset 
Alzheimer’s Disease consortium with the aim of develop-
ing 50 new rodent models based on human datasets and that 
better reflect AD pathology, with all data generated being 
publicly available.
Microglia in Alzheimer's disease
In 1908, Alois Alzheimer argued that microglia were impli-
cated in the pathogenesis of AD, based on observations of 
altered cell morphology in CNS tissue from patients [7]. 
Changes in microglia/macrophage morphology and den-
sity have been further linked to a variety of neurodegen-
erative illnesses, including Parkinson's disease (Fig. 1c) 
and amyotrophic lateral sclerosis (Fig. 1d–f), in addition 
to AD (Fig. 1g–i). The likely involvement of microglia in 
AD pathology, however, was not fully appreciated until 
the development of genome-wide association studies. This 
revealed that 60.4% of AD-risk single-nucleotide poly-
morphisms are highly expressed by microglia [212, 364], 
including Apoe, Trem2, Abca7, Cd33 and Cr1 [221]. More 
recently, single nuclei RNA sequencing on AD brains 
showed that out of seven cell types, gene expression changes 
were shown only in microglia [119]. Given the demonstrable 
link between microglia-expressed genes and AD, many stud-
ies have attempted to elucidate their precise functions in this 
disease using murine models, although remarkably, genetic 
studies have implicated microglia in almost every defined 
neurodegenerative disorder [221].
Role of DAMPs and microglia in promoting low‑grade 
inflammation and neurodegeneration
While DAMPs are thought to be beneficial in acute inflam-
mation by protecting the CNS from pathogen evasion and 
tissue damage [178], in AD, the chronic release of DAMPs, 
mitochondrial-released DAMPs and pro-inflammatory mol-
ecules contributes to the onset and progression of neuro-
degeneration [57, 76, 97, 149, 194, 270, 304, 333, 345]. 
The underlying mechanism likely involves the binding of 
these molecules to microglia-expressed receptors, caus-
ing self-perpetuating microglial activation with sustained 
release of pro-inflammatory mediators. This is thought to 
divert microglia from performing house-keeping functions, 
promoting a low-grade inflammatory state and CNS damage 
[149, 333]. Collateral damage to proximal neurons perpetu-
ates this cycle via the further release of DAMPs [57] and 
potentially the progression of neurodegeneration. Indeed, the 
DAMP, high-mobility-group box protein 1 is elevated in the 
sera of AD patients and correlates with levels of Aβ in the 
CNS [97]. Notably, microglial-expressed Mac-1, a potential 
receptor for high-mobility-group box protein 1, is increased 
in expression in AD brains [5] with ligand–receptor bind-
ing resulting in the production ROS and pro-inflammatory 
molecules [110]. This suggests a role for this DAMP in per-
petuating chronic inflammatory signalling in the CNS and 
the progression of AD [57].
It is unclear what causes the initial release of these mol-
ecules, which sustains a low-grade inflammatory response 
in the brain. However, studies have shown that cellular 
aging, infection, traumatic brain injury, systemic inflam-
mation, chronic inflammatory diseases, obesity and poor 
oral health occurring during middle adulthood can lead to 
increased pro-inflammatory signals in the periphery, which 
may contribute to glial activation and the onset and/or per-
petuation of neurodegeneration [93, 105, 149, 333]. Indeed, 
lipopolysaccharide (a major gram negative bacterial cell 
wall component)-induced inflammation in mice with amy-
loidosis or tauopathy increased neuropathology [187, 283]. 
Targeting neuroinflammatory processes and the activation of 
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innate immune responses which are paradoxically protective 
in acute inflammatory scenarios may provide a necessary 
therapeutic approach to AD.
Role of microglia in the formation and clearance of Aβ 
plaques
Both in human AD and its mouse models, microglia sur-
round Aβ plaques [216, 226, 365]. Although more human 
studies are required, the local function of these cells appears 
to be bidirectional, with microglia having both protective 
and pathological functions. Microglia are thought to con-
tribute to the formation of plaques while also compacting 
and clearing Aβ deposits to prevent damage to neighboring 
neurites. See Table 5 for a comparison of the protective and 
pathogenic roles of microglia in AD, as well as their disease-
associated transcriptomes and immune profiles.
Microglia contribute to the phagocytic and enzymatic 
clearance of Aβ plaques [82] in concert with resident 
perivascular macrophages [311, 356]. These cells also have 
a role in compacting Aβ to potentially prevent their spread 
and impact on local neurites. Indeed, microglia depletion in 
four-month-old humanized APP mutant knock-in homozy-
gote  (APPNL−G−F) mice resulted in reduced plaque compac-
tion and increased plaque volume, number, and size, dem-
onstrating that microglia play an essential role in plaque 
compaction between four to six months of age in mice [61]. 
The increased Aβ burden with age suggests that microglia 
become senescent and are unable to phagocytose Aβ or that 
their ability to do so becomes latent [101, 302]. Indeed, 
microglia ablation in AD mouse models at 10 months of 
age had no impact on plaque burden, suggesting that these 
cells are dispensable for Aβ clearance and plaque formation 
in the late stage of disease [296]. To overcome this so-called 
latency, administration or expression of IFN-γ, TNF or IL-6 
in the mouse CNS reduced Aβ deposition [48–50], poten-
tially stimulating microglial phagocytosis and clearance of 
Aβ from the brain.
In contrast to the protective roles of microglia in AD, 
such as the clearance and compaction of Aβ, microglia 
can also contribute to Aβ deposit formation early in dis-
ease. Microglial ablation using PLX3397 in two-month-
old 5xFAD mice [294] or PLX5622 in 1.5-month-old 
5xFAD [295] mice prevented intraneuronal amyloid and 
neuritic plaque formation [294] and significantly reduced 
plaque formation [295], respectively (Fig. 4 and Table 5). 
Ablation of microglia in younger mice before develop-
ment of cerebral amyloidosis thus reduces Aβ deposition 
[294], while ablation of microglia later in disease (i.e., 
in 10-month-old 5xFAD mice) [296], does not alter Aβ 
load. Interestingly, a fraction of microglia in the thalamus 
were resistant to 10 weeks of PLX5622 treatment and were 
associated with the few plaques that had formed [295]. 
Thus, even a small number of microglial cells are sufficient 
to initiate plaque pathology. It has been suggested that 
microglial lysosomes provide a suitable environment for 
Aβ aggregation. Indeed, Aβ aggregates were found within 
the lysosomes of microglia in brain regions where plaques 
Fig. 4  Protective and pathogenic roles of monocytes and micro-
glia in neurodegeneration. a Protective functions. In AD, micro-
glia and  Ly6Clo monocytes reduce parenchymal and vascular Aβ 
spread, respectively. b Pathogenic functions. Microglia phagocytose 
C3-tagged synaptic termini via C3R, leading to neurodegeneration 
and cognitive dysfunction in post-infectious encephalitis, AD, EAE 
and MS. Aβ amyloid beta; AD Alzheimer’s disease; C3 complement 
component 3; C3R complement component 3 receptor; EAE experi-




were not yet formed in non-PLX5622-treated 5xFAD mice 
[295]. However, Aβ deposition can also be observed in 
regions of the brain devoid of microglia, including the 
dura mater, choroid plexus and perivascular space [71, 
253], suggesting that microglia may not be the only cells 
contributing to Aβ plaque aggregation.
Role of microglia in tau‑related pathology
It has recently been suggested that AD progression is better 
correlated with tau pathology, neuronal degeneration, Aβ 
spreading and synapse loss, rather than Aβ detection alone 
[222]. While the role of microglia in tau-related pathol-
ogy is relatively understudied compared to their role in Aβ 
formation and clearance [328], it has been suggested that 
microglia may also contribute to tau pathology. Microglial 
expression of pro-inflammatory mediators and release of 
extracellular vesicles have been shown to promote the patho-
logical spread of tau.
Consistent with this, tau pathology was reduced by inhib-
iting microglial activation via overexpression of CX3CL1, 
a chemokine released by neurons that binds to microglial-
expressed CX3CR1 [240] or by administration of anti-
inflammatory drugs [113]. Conversely, promoting microglia 
activation via lipopolysaccharide- or virus-induced inflam-
mation promoted tau pathology [187, 304]. Fascinatingly, 
microglial activation can even induce tau accumulation in 
wild-type mice with no induced tauopathy [112], strongly 
supporting the importance of microglia-mediated inflamma-
tion in initiating tau pathology. Although the exact mecha-
nisms that cause microglial activation are unknown, it is 
possible that the low-grade chronic inflammation (described 
above) that occurs in middle-aged individuals promotes 
neuroinflammation and the progression of tau pathology 
[57, 97, 194, 304, 333]. Tau oligomers and monomers can 
also activate NLRP3 inflammasomes, further perpetuating 
microglial activation [162] and potential progression of tau 
pathology. While more human studies are required, it is clear 
from murine models that microglia have an indirect role in 
promoting tau accumulation via expression of pro-inflam-
matory mediators.
Microglia have also been implicated in the pathological 
spreading of tau via the release of extracellular vesicles [12, 
61, 328]. While human and microglia can internalise aggre-
gated or hyperphosphorylated tau for protein degradation, 
they can also release incompletely degraded or un-neutral-
ised forms back it into the extracellular space, promoting 
the spread of tau [12, 32, 36, 108, 153]. Indeed, depletion of 
microglia in mice injected with tau-expressing adeno-associ-
ated virus reduced tau propagation, which was hypothesized 
to occur by ablating microglial-mediated phagocytosis and 
subsequent re-secretion of tau-laden exosomes for the patho-
logical spread and accumulation of tau.
To study the mechanistic link between microglial-medi-
ated tau propagation and amyloid accumulation, microglia 
were depleted in  APPNL−G−F mice injected with tau-express-
ing adeno-associated virus [61]. Intriguingly, microglia were 
shown to be three times as phagocytic and three times more 
likely to release tau-containing extracellular vesicles when 
situated near amyloid plaques [61]. This was associated with 
enhanced tau propagation in mice with amyloidosis, com-
pared to wild-type mice without amyloidosis [61], highlight-
ing the importance of studying both amyloid- and tau-related 
pathological features of AD in one model. Interestingly, 
microglia depletion had no effect on tau in aged mice [27]. 
This could suggest that microglia become senescent and can-
not phagocytose tau, potentially leading to decreased extra-
cellular vesicle production and tau spread. However, results 
from this study may have been confounded by incomplete 
microglial depletion, which was only ~ 30% [27].
Tau accumulation is frequently associated with synaptic 
loss. Microglia can phagocytose tau-laden synapses or entire 
neurons [36, 75], promoting neurodegeneration and memory 
loss. As previously mentioned, microglial-expressed com-
plement components, including C1q, are thought to bind to 
synapses and enable phagocytosis by microglia [75, 103]. 
While more investigation in the human is required to confirm 
microglial association with C1q-mediated tagging of syn-
apses, in normal aging [300] and in tauopathy patients [75], 
C1q is dramatically upregulated and is shown to co-localize 
with hyperphosphorylated tau, plaques and neurofibrillary 
tangles in AD brain sections [1, 219, 282]. Together, this 
work suggests that while microglia attempt to perform physi-
ological functions, such as clearing pathological tau and Aβ 
aggregates, these proteins may be incompletely degraded 
and re-secreted into the extracellular space to spread protein 
accumulation. These proteins can also bind microglial recep-
tors, promoting pro-inflammatory signalling and diverting 
microglia from house-keeping functions, thereby causing 
a self-perpetuating chronic inflammatory response that 
induces further protein accumulation and tau seeding.
The ‘universal’ neurodegenerative microglial phenotype
Recent transcriptomic studies have identified a subset of 
microglia that adopt unique transcriptional and functional 
signatures, termed ‘disease-associated microglia’ (DAM) 
[179] or ‘microglial neurodegenerative’ (MGnD) phenotype 
during neurodegeneration [191]. These microglial signatures 
are characterised by the downregulation of homeostatic 
genes (P2ry12, Tmem119, Sall1 and Cx3cr1) and upregula-
tion of an inflammatory program (Trem2, Apoe, Axl, Lpl 
and Clec7a) (Table 5), several of which have been identi-
fied in genome-wide association studies linked to human 
AD. The DAM phenotype has been proposed to represent a 
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universal and intrinsic microglial response program to CNS 
disease, since it appears to be retained across a number of 
neurodegenerative and non-neurodegenerative diseases [74, 
291]. However, it remains unclear if this intrinsic response 
program specifically identifies a functionally meaningful 
subset, and whether it is beneficial or detrimental to disease 
pathogenesis.
Several studies have suggested that the microglial DAM 
signature is protective in neurodegeneration. This has 
been highlighted by the importance of TREM2, a recep-
tor expressed by DAM/MGnD, which exerts its protective 
function in AD via ligation of ApoE (apolipoprotein E), 
which binds to loose Aβ aggregates, or direct ligation of 
Aβ oligomers [286, 295, 338, 357, 366]. This process ena-
bles lysosomal degradation and phagocytotic trimming of 
Aβ by surrounding microglia, which may be crucial to the 
compaction (but not removal) of developing Aβ deposits 
to protect neurons from injury (Table 5). Accordingly, AD 
patients carrying mutations in TREM2 genes display less 
compact Aβ plaques and fewer plaque-associated microglia 
but enhanced tau pathology and neuritic plaques [191, 361]. 
Similarly, in mice with cerebral amyloidosis, genetic abla-
tion of TREM2 abrogated the MGnD phenotype and reduced 
the microglial response to plaques [191]. This supports a 
protective role for the DAM/MGnD microglial phenotype, 
with TREM2-dependent functions potentially required ini-
tially to prevent seeding of plaques, whilst later enhancing 
the consolidation of Aβ into compact aggregates to protect 
neurons from Aβ-induced injury. This protective function 
appears to be independent of other microglia-mediated func-
tions which are detrimental to neurons, such as their contri-
bution to synapse loss.
Other studies instead argue that the microglial DAM/
MGnD phenotype is damaging. It is known that homeostatic 
microglia support neuron maintenance [211, 306]. Thus, 
the phenotypic transition observed in DAMs may harm 
neurons by causing low-grade inflammation and lowering 
neurotropic support, which may contribute to increased tau 
phosphorylation [82]. In support of this, gene expression 
analysis showed that pathways related to neuronal function 
(i.e., glutamate receptors, synaptic vesicles, and neuronal 
membranes), were downregulated in the hippocampus of 
5xFAD mice [295]. This pattern was reversed in the absence 
of microglia, suggesting that these cells restrict gene expres-
sion pathways crucial to neuronal function in AD [295]. 
Furthermore, complement activation, which is important 
for microglial phagocytosis, can exacerbate synaptic loss 
[152, 284, 291] and contribute to memory loss and cogni-
tive decline [75] (Table 5). Consequently, microglia deple-
tion before or after the formation of Aβ pathology in mouse 
models of AD resulted in improved contextual memory, 
further implicating microglia in neuronal and/or synaptic 
loss [294–296].
The ability of microglia to return to homeostasis during 
AD may be impaired by the downregulation of the micro-
glial receptors CX3CR1 and CD200R, which bind to neu-
ronal ligands and act as immune checkpoints that maintain 
microglia homeostasis [30]. Furthermore, DAM-expressed 
factors, such as apolipoprotein, colony-stimulating factor 
1 (CSF1) and secreted phosphoprotein 1, act as autocrine 
ligands on DAM-expressed receptors, together sustaining 
and perpetuating the neurodegenerative phenotype [291]. 
Thus, both protective and pathogenic functions are likely 
to be carried out simultaneously by the DAM phenotype.
Relevance of DAM/MGnD to human AD
The importance of the DAM/MGnD phenotype must be 
more carefully considered in the context of human pathol-
ogy. In contrast to mouse studies, single cell nuclei extrac-
tion from frozen human brain tissue revealed 13 distinct 
microglial clusters [119]. While a population of clusters, 
namely AD1, closely reassembled the mouse DAM/MGnD 
phenotype, it was only abundant in human samples contain-
ing Aβ and not tau. Conversely, AD2 did not overlap with 
AD1 and was more frequently observed in human brain 
samples showing both tau and amyloid pathology [119]. 
These data highlight the usefulness of amyloidosis mouse 
models in exploring the human AD1 (DAM-like) pheno-
type; however, it demonstrates that the additional presence 
of tau in the CNS could induce a different microglial phe-
notype. This may explain why single-cell RNA-seq analysis 
on 16,242 live microglial cells isolated from the aging and 
AD human brain demonstrated an overall weak correlation 
with the DAM signature [246]. Together this work dem-
onstrates, firstly, that there exist other microglial subsets 
in AD besides the DAM/MGnD phenotype, and secondly, 
that human microglia are heterogenous, thus limiting the 
translation of the DAM signature from animal models. This 
therefore highlights the need for improved mouse models 
that better replicate human AD and/or that further investiga-
tion is required of other non-DAM/MGnD phenotypes in the 
diseased mouse brain.
In support of these conclusions, other microglial phe-
notypes beyond the DAM/MGnD have been discovered 
in murine models of CNS pathology [106, 264]. Perhaps 
these different microglial transcriptional programs feature 
in different aspects of AD pathology, as shown in a human 
study where it was thought that one microglial transcrip-
tional program contributed to tau pathology and two others 
to β-amyloid pathology [252].
The role of microglia in AD is clearly complex. Neverthe-
less, despite the disconnect between human and mouse mod-
els, without experimental modelling, we would never have 
understood certain aspects of the human pathology. Cur-
rent murine models suggest that microglia contribute to the 
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formation of plaques and tau aggregates, as well as neuronal 
damage and synapse loss. On the other hand, microglia have 
a role in phagocytosing pathological tau and compacting Aβ 
aggregates to prevent local neuritic damage. This may reflect 
an overall attempt to protect the brain by slowing down dam-
age, but ultimately persistent and low-grade inflammatory 
signals, as well as the continued accumulation of Aβ and tau 
aggregates, interfere with CNS functions. Taken together, 
several lines of evidence indicate that microglia play a sub-
stantially pathogenic role in AD, which appears to be in stark 
contrast to the overall effect of these cells in viral encepha-
litis and stroke. One obvious explanation for this lies in the 
acute versus chronic nature of these diseases.
Monocytes in Alzheimer's disease
The role of peripherally derived monocytes in neurodegen-
erative disorders such as AD has long been debated. It is 
unclear if and to what extent monocytes infiltrate the brain 
in neurodegenerative disorders, which feature low-grade 
inflammation rather than the severe, acute inflammation 
seen in viral encephalitis and ischemic stroke. This problem 
is complicated further by the difficulties of distinguishing 
peripherally-derived monocytes from resident microglia in 
human tissues histologically (Fig. 1g–i), as previously noted 
in other diseases.
The contentious involvement of monocytes in AD 
pathology
Findings supporting a neuroprotective role for monocytes in 
AD pathology are conflicting and have been confounded by 
the use of experimental systems that condition the brain for 
monocyte infiltration, thereby preventing the accurate rep-
resentation of disease pathophysiology. For instance, studies 
utilizing whole body irradiation chimeras, an experimental 
technique that is now recognized to condition the brain for 
monocyte infiltration [2, 3, 230], as well as transplant of 
BM-derived cells, reported that  Ly6Chi monocytes infiltrate 
the AD mouse brain and accumulate around Aβ plaques. 
These infiltrating cells were thought to ameliorate disease 
evolution by phagocytosis and clearance of Aβ from the 
brain parenchyma [287] or by promotion of CCR2-mediated 
microglial accumulation in amyloid plaques and degradation 
of Aβ [89]. Although it is unclear whether transplanted cells 
or monocytes engrafted the AD brain, this hypothesis was 
supported by observations that CCR2 deficiency worsened 
AD pathology [89, 238], presumably due to an inability to 
recruit  Ly6Chi monocytes from the BM [280]. However, sub-
sequent parabiosis experiments using head-protected irradia-
tion chimeras [229] or chemotherapy-induced myeloablation 
[227], which avoid the brain conditioning discussed above, 
demonstrated that  Ly6Chi monocytes are not recruited to 
the brain parenchyma during the course of AD. Subsequent 
studies further revealed that parenchymal Aβ burden is unal-
tered in CCR2-deficient mice [229, 238], further exonerat-
ing  Ly6Chi monocytes from the responsibility for clearing 
Aβ in AD. Moreover, in a transgenic CD11b-HSVTK mouse 
model, in which ganciclovir administration “paralyses” 
 CD11b+ cells including microglia (i.e., where proliferation 
and activation is blocked), engrafted BM-derived monocytes 
failed to accumulate around Aβ plaques and did not reduce 
Aβ plaque burden [262]. Taken together, these findings sug-
gest that  Ly6Chi monocytes either do not infiltrate the brain 
parenchyma in large enough numbers to alter parenchymal 
Aβ burden, or these cells do not participate in Aβ phagocy-
tosis or clearance once in the brain.
Despite their lack of local involvement in the brain, blood 
monocytes may play an important role in the periphery. It 
is estimated that approximately 50–62% of Aβ diffuses into 
the blood [252, 261] and is thus cleared from the CNS [336, 
353]. Monocytes in the peripheral circulation showed a 
reduced Aβ uptake capacity with age and in AD patients 
[56], implying that impaired Aβ uptake by monocytes may 
play a role in the aetiology of AD. Several human AD risk 
gene variants have been linked to monocytes, including 
those related with TREM2 and CD33 [34, 52], the latter of 
which is linked to diminished Aβ internalization by periph-
eral monocytes [34].
The importance of peripheral monocytes in Aβ clear-
ance is supported by experimental studies demonstrating 
that peripheral  Ly6Clo monocytes likely contribute to Aβ 
clearance from the cerebral vasculature, thereby indirectly 
reducing parenchymal Aβ burden [227] (Fig. 4). By intravi-
tal two-photon imaging, patrolling  Ly6Clo monocytes were 
shown to participate in Aβ clearance from the leptomenin-
geal vasculature [227]. These cells selectively crawl along 
Aβ-laden veins and scavenge Aβ from the lumen. Depletion 
of these cells by deletion of Nr4a1, a transcription factor 
controlling the differentiation and survival of  Ly6Clo mono-
cytes [144], corresponded with increased Aβ deposits in the 
cortex and hippocampus [227], implicating a critical role for 
vascular Aβ clearance by patrolling monocytes. The protec-
tive function of  Ly6Clo monocytes in AD may also explain 
why CCR2 deficiency exacerbates disease severity [89, 238], 
as  Ly6Clo monocytes, which differentiate from recruited 
 CCR2+Ly6Chi monocytes in the bloodstream, would no 
longer be recruited to this function [323, 359]. On the other 
hand, yolk sac-derived perivascular macrophages also clear 
Aβ from the vasculature [147] in a CCR2-dependent man-
ner [229], and impaired Aβ clearance by these cells would 
presumably also contribute to the accelerated disease pro-
gression observed in CCR2-deficient mice.
In addition to their role in Aβ pathology, monocytes may 
participate in the low-grade, systemic inflammation that can 
accompany aging and cognitive decline in AD. Although 
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overall peripheral blood monocyte counts do not appear to 
vary over disease course, there are population shifts in mono-
cyte subsets in patients with AD [312]. This is evidenced by 
a decrease in classical monocytes  (Ly6Chi in mice) and an 
increase in intermediate and non-classical monocyte popu-
lations  (Ly6Clo in mice) with disease progression, which 
coincided with a shift in monocyte pro-inflammatory gene 
expression (including IL6, TNF and ILLB) [312]. Moreover, 
IL-33 signalling shown to reduce synaptic impairment and 
subsequent memory deficits in APP/PS1 mice was impaired 
in lipopolysaccharide-primed and Aβ-stimulated monocytes 
from patients with AD dementia [275], further suggesting 
that an altered monocyte phenotype may contribute to AD 
pathology.
Demyelinating disease
Multiple sclerosis is an inflammatory demyelinating disease 
of the CNS, thought to be of autoimmune aetiology, char-
acterised by chronic neuroinflammation and neurodegen-
eration. It involves the progressive loss of oligodendrocytes 
and neurons, resulting in motor and cognitive deficits [322, 
326]. Clinical displays of MS are highly heterogeneous and 
can comprise clinically isolated syndromes, primary pro-
gressive forms and relapsing–remitting patterns, the latter 
causing ~ 85% of initial cases and potentially developing into 
secondary progressive MS over a span of 10–15 years [309, 
346]. Relapsing–remitting MS is characterised by episodes 
of neurological impairment followed by stages of remission 
and partial neurological recovery, while progressive MS 
forms involve progressive neurological impairment without 
phases of remission [326, 346]. The extensive infiltration 
and activation of peripheral and resident immune cells in MS 
suggests these cells are key mediators of lesion formation 
[77, 210, 278] (Fig. 1j-l). However, mirroring the heteroge-
neity of clinical presentation, different classes of lesion exist, 
depending on disease type, duration, cellular players and 
anatomical compartment [205, 256], making this complex 
scenario challenging to mimic in a single animal system 
[40, 186, 196].
Relevance of murine models to human MS
Similar to other CNS pathologies, MS is a uniquely human 
disease, and as such can only be partially modelled in 
experimental animal systems [186]. Significant caution is 
thus necessary in interpreting results from animal models, 
in particular from the widely used murine Experimental 
Autoimmune Encephalomyelitis (EAE) model. Inflam-
mation in EAE is primarily mediated by MHC class II-
restricted autoreactive T cells that are induced by injection 
of encephalitogenic antigens (e.g., myelin basic protein, 
myelin oligodendrocyte glycoprotein, MOG, or proteolipid 
protein, PLP), in conjunction with an adjuvant, or passively, 
via peripheral administration of encephalitogenic  CD4+ T 
cells [64]. APCs play an important role in the activation 
of peripherally-primed T cells, resulting in an inflamma-
tory cascade that leads to oligodendrocyte death, chronic 
demyelination, and neuronal loss [64, 77]. While commonly 
referred to as a single experimental paradigm, EAE develop-
ment and pathological presentations are critically dependent 
on the induction method, animal strain and genetic manip-
ulations [40, 186]. Most groups however, utilize C57Bl/6 
mice, a strain typically developing an acute, monophasic 
disease useful to study the main inflammatory aspects of 
acute MS [232]. Depending on the specific model, EAE fails 
to fully recapitulate the complex pathological presentation of 
MS, including the differential distribution of lesions between 
brain and spinal cord, the driving lymphoid cellular com-
ponents, and the relative extent of demyelination in white 
matter tracts [265].
Furthermore, most EAE models do not recapitulate the 
extensive grey matter pathology observed in patients, which 
show a demyelination pattern often characterized by chronic 
microglia activation, absence of leukocyte infiltration [46] 
and pronounced meningeal inflammation [156]. While novel 
models have recently been developed to study this type of 
lesion [318], other experimental approaches are better suited 
to model a subtype of inflammatory grey matter pathology 
observed in early MS cases [256] and displaying tissue-
invading leukocytes supposedly driving local damage [169, 
180, 203, 225]. At the same time, even though attempts to 
represent a chronic disease course have been made [23], and 
mouse strains, such as Biozzi ABH [6] and A.SW [314], 
show a clinical development resembling progressive MS, 
most EAE models are not suited to mimic primary/second-
ary progressive pathology or general disease chronicity. For 
instance, EAE induction in non-obese diabetic (NOD) mice, 
often claimed to represent the clinical course of progressive 
MS, can be used to study some neurodegenerative aspects of 
the disease, but overall it lacks evidence as a valid chronic 
model [15]. Taken together, the need remains for novel 
experimental approaches that better model progressive and 
chronic MS.
Notwithstanding these drawbacks, EAE has proved of 
unmatched value for the understanding of several pathologi-
cal mechanisms evidently occurring in the human disease; 
furthermore, it still represents the best platform to test novel 
therapeutic approaches [186]. Research in EAE models has 
for instance directly led to the development of the disease 
modifying therapies, glatimer acetate and natalizumab, 
while other drugs, such as fingolimod, dimethylfumarate 
and alemtuzumab, have been tested and mechanistically 
explained, thanks to this model [186]. On the other hand, 
an important number of therapies stemming from EAE 
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studies, in particular most approaches involving manipula-
tion of cytokine actions, have surprisingly and consistently 
failed successful clinical application, once again showing the 
context-dependent limitations of EAE [265].
Other aspects of MS, such as demyelination in the rela-
tive absence of adaptive immunity-driven inflammation, 
are alternatively studied using chemical- (i.e., lysolecithin-
induced) [352] or toxin- (i.e., cuprizone) mediated demyeli-
nation models [257]. Other groups have instead used diph-
theria toxin-induced death of oligodendrocytes to mimic 
the formation of lesions in some early MS cases, showing 
oligodendrocyte apoptosis in the absence of immune cell 
infiltration [17, 202, 313]. The spontaneous development of 
demyelination seen with viral infection, e.g., TMEV infec-
tion, is also a useful model to study specific neurodegenera-
tive characteristics seen in MS [118].
Microglia in multiple sclerosis
Akin to many neuroinflammatory diseases, the “empirical 
observation of microgliosis” implicates a role for microglia 
in MS pathogenesis [132]. Indeed, the number of ‘activated’ 
microglia and macrophages correlates with axonal damage 
in MS lesions [31, 99, 267, 327]. Interestingly, however, 
gene expression patterns from human brain data at the tis-
sue-level did not show an enrichment in MS susceptibility 
genes [161]. Extending the analysis to include data gen-
erated from human induced pluripotent stem cell-derived 
neurons, astrocytes and microglia, revealed the enrichment 
of MS susceptibility genes in microglia but not astrocytes 
or neurons [161]. The CLECL1 locus implicated a role for 
microglia in MS pathogenesis, which was underestimated 
in tissue-level brain profiles. The role of microglia in MS 
however remains unclear and might be dependent on the 
type and chronicity of distinct lesions. Several insights into 
microglia function could be inferred from animal studies, 
despite obvious limitations and potential species-related cel-
lular differences [138].
Duality of microglial roles in immune or chemical 
demyelination
A detrimental role for CNS-resident macrophages in EAE 
was first suggested in a transgenic mouse model of so-called 
“microglial paralysis” (i.e., where proliferation and ‘activa-
tion’ is blocked) in lethally irradiated, CD11b-HSVTK mice 
engrafted with wild-type BM, that showed reduced EAE dis-
ease severity [150]. However, the interpretation of these data 
was hampered by the observation that CD11b-HSVTK ani-
mals also displayed reduced CNS infiltration of peripheral 
leukocytes. Considering that CCR2 blockade/deficiency [2, 
228], clodronate liposome or immune-modifying nanopar-
ticle administration, all of which abrogate CNS infiltration 
of  Ly6Chi monocytes and result in attenuated EAE signs 
[121, 233], this implies a key function of  Ly6Chi monocyte-
derived cells in EAE development, leaving a potential patho-
genic or protective role for microglia in the CD11b-HSVTK 
model unresolved. Subsequently, a study in which mice 
were fed high- and low-dose PLX5622 post-EAE induction 
showed improved disease signs without affecting periph-
eral immune cell populations. PLX5622-treated mice also 
showed an increase in mature oligodendrocytes, suggesting 
a role for microglia in regulating oligodendrocyte maturation 
[243] (Fig. 5 and Table 6).
The exact role of microglia in EAE is unclear. However, 
it appears that microglial ‘activation’ and production of pro-
inflammatory mediators have a role in the pathogenesis of 
the disease (Fig. 5). Pellino-1-deficient (Peli1−/−) mice were 
refractory to EAE induction [354] (Table 6). Peli1, expressed 
by microglia in the brain and upregulated during EAE, is an 
E3 ubiquitin ligase that enhances Toll-like receptor/MyD88 
signaling via the degradation of the adaptor protein TRAF3 
and the activation of the mitogen-activated protein kinase, 
with the consequent induction of several pro-inflammatory 
cytokine (Il1b, Tnf, Il12b) and chemokine (Cxcl1, Ccl2, 
Ccl20) mediators. However, other CNS-resident and infil-
trating macrophage populations may also express Peli1, thus 
deficiency of Peli1, which reduces EAE severity, implicates 
both microglial and non-microglial cells in the production 
of inflammatory mediators and the pathogenesis of EAE. 
Further, non-physiological effects, created in the genera-
tion of the Peli1 knockout chimera via lethal irradiation and 
by disrupting the function of Peli1 during development and 
adulthood in all cell types cannot be ruled out.
Using more selective tools to target microglia dur-
ing neuroinflammation, Goldmann et al. [129] generated 
Cx3cr1CreER:Tak1fl/fl mice, whereby TGF-β-activated kinase 
1  (TAK1) was ablated from long-lived  CX3CR1+ cells 
(which include microglia) [129]. TAK1 is a mitogen-acti-
vated protein kinase kinase kinase, upstream from nuclear 
factor-κβ, which upon activation can induce the production 
of cytokines, chemokines and adhesion molecules, contrib-
uting to inflammation and the recruitment of immune cells. 
Genetic ablation of TAK1 in long-lived  CX3CR1+ cells 
attenuated EAE pathology [129]. This was associated with 
reduced cellular infiltration into the CNS, reduced myelin 
destruction and axonal loss, and suppression of proinflam-
matory genes. Using a more targeted approach to study 
microglia, this study supports the pathogenic role of these 
cells in EAE via the production of inflammatory mediators. 
This is in line with studies using less selective tools, i.e., the 
Peli1 knockout chimera, mentioned above.
More recently, using single-cell technology, a subpop-
ulation of microglia was identified in the CNS of mice at 
the onset of EAE which produced ROS [224]. The pro-
duction of ROS contributes to oxidative stress and injury 
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associated with myelin damage and disease progression in 
MS. Using Tox-RNA sequencing to transcriptionally pro-
file ROS-producing cells, Mendiola et al. [224] identified 
an oxidative stress signature (Cybb, Ncf2, Ncf4 and Gpx1) 
shared by all MC populations and one microglia popu-
lation in EAE [224]. Targeting these populations with 
acivicin, which targets γ-glutamyl transferase to degrade 
anti-oxidant glutathione, decreased disease severity in 
four models of EAE and a model of microglia-driven neu-
rodegeneration (induced by a lipopolysaccharides injec-
tion in the substantia nigra) [224]. Thus, this study shows 
that at least one subpopulation of microglia in EAE is 
neurotoxic, contributing to oxidative stress and pathology.
On the other hand, using Csf1−/− mice to reduce the 
number of white matter microglia, lysolecithin-mediated 
demyelination resulted in extensive demyelination and 
neuronal damage compared to WT controls, suggesting a 
protective role for microglia [352]. Csf1−/− animals also 
showed enhanced pro-inflammatory astrocytic responses, 
indicating that microglia can prevent dysfunctional astro-
cyte responses necessary for the inflammatory-to-regen-
erative switch required for the initiation of remyelination 
(Table 6). Thus, while differences could be due to the 
distinct microglial depletion and/or MS models used, this 
study nevertheless suggests a protective role for microglia 
in promoting remyelination to prevent axonal damage, in 
contrast to the previously discussed reports.
Role of microglial CSF1R, TREM2 and P2X4R in EAE 
remyelination
As mentioned above, using high- and low-dose administra-
tion of the CSF1R inhibitor, PLX5622, Nissen et al. [243] 
revealed a pathogenic role for microglia in EAE, as clini-
cal presentation of the disease was reduced upon microglial 
depletion. Seemingly paradoxically, stimulation of CSF1R 
was also protective in EAE [347]. Recombinant IL-34 or 
recombinant CSF1 injected intrathecally via the cisterna 
magna ameliorated EAE, suppressing disease progression 
and severity and reducing demyelination and oligoden-
drocyte loss (Table 6). Notably, this corresponded with 
the expansion of  CD11c+ microglia, a population absent 
from the homeostatic CNS parenchyma but described to 
emerge in postnatal development in the neonatal brain, 
in cuprizone-induced demyelination, and in mouse mod-
els for neuromyelitis optica and AD [42, 268, 348, 350]. 
Fig. 5  Protective and pathogenic roles of monocytes and microglia 
in autoimmune neuroinflammation. a Pathogenic functions. Peli-
mediated microglial expression of pro-inflammatory cytokine and 
chemokines can exacerbate inflammatory damage to myelin. GM-
CSF-stimulated moDC activate myelin-reactive T cells and exac-
erbate myelin damage via the production of ROS and IL-1β.  iNOS+ 
MDM producing ROS and NO contribute to myelin destruction but 
may also transition to arginase-1+ MDM and facilitate the resolution 
of inflammation (b). b Protective functions. Microglia may stimulate 
re-myelination via P2X4R-mediated phagocytosis of myelin debris. 
GM-CSF granulocyte–macrophage stimulating factor; IL interleukin; 
iNOS inducible nitric oxide synthase; MDM monocyte-derived mac-
rophage; MHC major histocompatibility complex; moDC monocyte-
derived dendritic cell; NO nitric oxide; P2X4R P2X purinoceptor 4; 
Peli Pellino E3 Ubiquitin Protein Ligase; ROS reactive oxygen spe-
cies; TH T helper cell
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A  CD11c+ microglial population further characterized as 
 CD317+ MHC-II+  CD39hi  CD86+ was also previously iden-
tified by Ajami et al. [4] in the active phase of EAE and 
downregulated in the chronic phase or upon clinical recovery 
[4]. These cells seem to be important sources of insulin-
like growth factor 1 (IGF-1) and IFN-β, thus supporting a 
neuroprotective role for this population [348–350]. Accord-
ingly, deletion of IGF-1 in these  CD11c+ cells resulted in 
impaired primary myelination in the developing brain [349]. 
Thus, reduced demyelination seen with CSF1R stimulation 
was suggested to be a result of the expansion of a  CD11c+ 
microglia population, promoting myelination of axons.
Interestingly, EAE severity was enhanced in mice 
where  CD11c+ cells were depleted using several genetic 
approaches [358]. This was thought to be a consequence of 
a reduction in inducible Tregs due to depleted  CD11c+ DCs. 
However, the worsened disease outcome in the absence of 
CD11c may have been due to the inhibition of protective 
functions orchestrated by  CD11c+ microglia or even MCs.
The purinergic P2 receptor P2X4R, highly expressed 
by microglia at the peak and recovery phase of disease, 
has also been implicated in inducing efficient remyelina-
tion [362] (Fig. 5 and Table 6). In this work, daily admin-
istration of a P2X4R antagonist from the onset of disease 
exacerbated clinical signs of EAE by polarising microglia 
into a pro-inflammatory state. Conversely, potentiation of 
P2X4R using ivermectin, which modulates ion conduction 
and channel gating of P2X4Rs, ameliorated EAE motor 
deficits and improved corticospinal tract function. P2X4R 
signalling correlated with a higher phagocytic capacity by 
promoting an acidic shift in lysosomes, which could favour 
myelin clearance required for effective remyelination [362]. 
This study highlights the disease-ameliorating importance 
of myelin phagocytosis by microglia. Similarly, microglia 
pre-stimulated with IL-4 ex vivo and transplanted into the 
CSF, also resulted in oligodendrogenesis and amelioration 
of EAE [43]. However, the interpretation of this experiment 
warrants caution, considering the non-physiological condi-
tions associated with an intraventricular injection of in vitro-
derived microglia.
TREM-2 is an important receptor involved in phagocy-
tosis, and upon genetic absence or blockade of TREM-2, 
microglia fail to upregulate genes required for lipid metabo-
lism and phagocytosis, resulting in the exacerbation of EAE 
[254, 255] (Table 6). These studies further support a role for 
microglia in the phagocytosis of myelin debris and poten-
tially in subsequent axonal remyelination. Furthermore, 
gene expression studies in models of EAE support a role for 
microglia in apoptotic cell [199] and debris clearance [355].
The studies above demonstrate the pathogenic role of 
microglia in the acute phase of EAE, with polarisation of 
microglia to an anti-inflammatory phenotype, or expan-
sion of a  CD11c+ microglia population, reducing disease 
severity via indirectly promoting remyelination of axons 
and/or the phagocytosis of myelin debris. In contrast, in the 
toxin-induced model of demyelination in MS, microglia are 
protective, since microglial depletion results in an overexu-
berant astrocytic response and extensive demyelination.
Role of microglia in T cell priming and EAE pathogenesis
Microglia have also been implicated in presenting antigen to 
T cells in the early stages of disease, given that microglia are 
the first cells to take up myelin antigen [293], and can extend 
MHC-II+ cellular processes at the level of the glia limitans 
to potentially contact invading cells [173, 197]. T cell stimu-
lation requires co-stimulation by CD80, CD86 and CD40, 
which are upregulated by microglia, although to a lesser 
extent than on infiltrating MCs [37]. Recently however, a 
series of studies utilizing different transgenic approaches 
elegantly showed that MHC-II expression on CNS-resident 
microglia/macrophages is dispensable for T cell priming and 
EAE pathogenesis [125, 174, 236, 351]. Instead, although 
this topic remains debated, the aforementioned studies impli-
cated cDC2 type of APC in the initiation of EAE.
Protective role of microglia in models of progressive MS
To model the clinical presentation observed in secondary 
progressive MS patients, the NOD mouse immunized with 
 MOG35-55 peptide has often been used. NOD mice induced 
with EAE typically develop secondary progression occur-
ring ~ 30 days post immunization, following an acute attack 
at 14 days and remission by 20 days [309]. In this model, 
initiating PLX3397 treatment at 20 days post EAE induc-
tion increased mortality and exacerbated disease in immu-
nized mice without affecting the timing of the relapse phase. 
PLX3397 microglia-depleted,  MOG35-55-immunized NOD 
mice displayed enhanced inflammation, demyelination, 
axonal degeneration and a significant increase in the num-
ber of  CD4+ and  Ki67+ proliferating  CD4+ T cells. These 
observations potentially suggest an overall protective role for 
microglia in the development of secondary progressive MS, 
in contrast to the discussed pathogenic role of microglia in 
the acute phase of EAE [309] (Table 6).
However, MOG-immunized NOD mice mirror only some 
of the biological processes observed in chronic MS patients, 
and caution is obviously needed when translating these 
results to MS [15]. In a recent study, EAE was passively 
induced via injection of myelin basic protein (MBP)-specific 
T cell blasts in LEWzizi rats. These are Lewis rats on a zit-
ter rat background that partly mimic human aging and MS 
pathology, showing neurodegeneration, hypomyelination, 
microglia activation and iron accumulation [346]. Interest-
ingly, there was no exacerbation of disease, compared to 
Lewis controls, contradicting expectations that pre-existing 
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microglia activation and pathology (or ‘aging’) would be 
amplified and convert EAE into a chronic progressive dis-
ease. Pathology was instead redirected to the mesencepha-
lon, where LEWzizi animals showed T cell infiltration and 
enhanced demyelination, presumably due to T cells targeting 
pre-damaged areas. While this study suggested that EAE 
pathogenesis is unaffected by microglia pre-activation and 
‘aging’, further investigations and different models better 
suited to investigate chronic cell activation are required to 
confirm this.
Monocytes in autoimmune inflammation
Monocytes are recruited to plaques in MS [193] (Fig. 1j-l) 
and have long been considered to play a pathological role in 
EAE. These cells leave the BM and migrate to the CNS prior 
to disease onset, with their infiltration preceding the devel-
opment of paralysis and subsequent clinical manifestations 
of EAE [183, 228]. As the infiltration of monocytes into the 
CNS is mostly CCR2-dependent, CCR2-deficient mice have 
frequently been used to prevent their immigration into the 
brain and investigate their role in disease [260]. Accordingly, 
initial experiments with CCR2-deficient mice showed that 
these animals were resistant to EAE induction [98, 137, 165, 
230], which suggested peripheral monocytes play a crucial 
role in disease pathogenesis. How monocyte-derived effector 
cells contribute to disease pathogenesis is less clear; such 
cells may contribute to pathology directly, through inflam-
mation-mediated myelin destruction, or indirectly through 
activation of autoreactive T cells via antigen presentation. 
The protective and pathogenic functions of monocytes in 
MS, along with their respective immune profiles, are com-
pared to those of microglia in Table 6.
An unlikely role: monocyte antigen presentation 
for the initiation of EAE
In EAE, the activation of encephalitogenic T cells via the 
presentation of the encephalitogenic antigen is a critical step 
in disease induction [64]. Antigen is presented by CNS-res-
ident or immigrant APCs, which typically express MHC-II 
and co-stimulatory molecules, CD80 and CD86, required for 
 CD4+ T helper (TH) cell activation. Antigen presentation 
in EAE has been attributed to DC, however, distinguishing 
brain-resident cDC from peripherally-derived monocyte-
derived DC has challenged the accurate characterization of 
the antigen-presenting functions of these cell types in EAE 
[4, 18, 136, 174, 236]. As both peripherally-derived and 
CNS-resident myeloid cells have been implicated in antigen 
presentation to autoreactive T cells, definitive evidence of a 
non-redundant role for monocyte-derived APC in activating 
autoreactive T cells is lacking. It was recently demonstrated 
that, in contrast to the resident population, CNS-infiltrating 
myeloid cells showed prolonged interactions with T cells in 
the CNS and that their expression of MHC-II was essential 
for EAE development [174, 236]. Furthermore, myeloid-
derived DC are critical for the activation and differentiation 
of TH17 cells [189, 231]. This was further characterized by 
mass cytometry demonstrating that monocyte-derived sub-
populations characteristically expressed phenotypes involved 
in activating TH1 and TH17 cells at disease onset [4], sug-
gesting these cells play a key role in antigen presentation.
However, the critical antigen-presenting role of moDC 
in EAE pathogenesis has been challenged by in vitro stud-
ies demonstrating that moDC are less capable of presenting 
myelin compared to cDC, and are therefore redundant in 
activating autoreactive T cells [125, 236]. The suggested 
relative inability of monocytes to present myelin peptide to 
autoreactive T cells has been explained by a lower expres-
sion of H2M [125], a non-classical MHC molecule facili-
tating the processing and presentation of myelin antigen 
[289]. Nonetheless, the distinction between moDC and 
cDC in vivo remains challenging because of overlapping 
phenotypic markers, complicating the resolution of their 
antigen-presenting functions in vivo and warranting further 
investigation.
Monocyte subsets participate in inflammatory myelin 
damage
In addition to possible antigen-specific T cell-mediated 
inflammation, non-specific inflammation also contributes 
to myelin destruction in MS [77]. Both CNS-infiltrating 
monocytes and resident microglia have been implicated in 
this process [133, 242], however, dissecting their respective 
functions in disease has proved difficult. To distinguish these 
cells during neuroinflammation, Ccr2rfp::Cx3cr1gfp reporter 
mice were used to distinguish  CCR2+ monocyte-derived 
cells from the resident  CX3CR1+ population in EAE, based 
on their differential expression of RFP and GFP [355]. 
Using this method, resident microglia appeared to be more 
involved in phagocytosing myelin debris and tissue repair, 
whereas MDMs in the immediate vicinity of axons at the 
nodes of Ranvier expressed a pro-inflammatory gene signa-
ture [355], suggesting that these cells actively participate in 
inflammatory myelin damage.
High-parameter technologies have further elucidated the 
heterogeneity of monocyte phenotypes driving inflammatory 
damage in EAE. It was recently demonstrated that CNS-
infiltrating monocytes adopt a toxic phenotype that likely 
mediates tissue damage [224]. Oxidative stress results from 
a metabolic switch during inflammatory activation that sus-
tains the production of inflammatory mediators, such as 
ROS and NO [109], which is required for pathogen defence 
functions. In EAE, however, this oxidative stress signa-
ture is associated with inflammatory damage, a phenotype 
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expressed by more than 50% of CNS-infiltrating monocytes 
[224]. The pathogenic function of this oxidative stress phe-
notype was emphasized by experiments demonstrating that 
inhibiting ROS production via inhibition of γ-glutamyl 
transferase, an upstream modulator of the oxidative stress 
pathway, reduced disease severity, decreased demyelination 
and axon damage, and lowered oxidative stress markers in 
multiple rodent models of MS [224], and may be a potential 
therapeutic target for human disease. However, these same 
cells primed to produce reactive species can be polarized 
from a pro-inflammatory  (iNOS+) to a tissue-repair (argin-
ase-1+) phenotype by the tissue microenvironment and move 
inflammatory lesions towards resolution, as demonstrated 
by single-cell fate-mapping. Therefore, therapeutic target-
ing of these cell types should be approached with caution, 
especially if the same monocytes expressing a pathogenic 
phenotype are central to the resolution of inflammation at a 
later stage in disease [201].
Single-cell RNA-sequencing has further revealed highly 
specialized monocyte subsets with distinctive functions in 
disease. Of these subsets, two newly identified Cxcl10+ and 
Saa3+ monocyte subsets expressing a pro-inflammatory sig-
nature were observed at the peak of disease [124]. These 
subsets were almost completely depleted by anti-CCR2 
antibody administered at the peak of disease and correlated 
with an overall clinical improvement, suggesting these cells 
possess a characteristic pathogenic potential. Of note, these 
pathogenic monocyte subsets may not be derived from 
 Ly6Chi monocytes, since adoptive transfer of BM monocyte 
progenitors demonstrated that Saa3+ and Cxcl10+ monocyte 
subsets differentiated from granulocyte-monocyte progeni-
tors and monocyte-macrophage DC progenitors evidently 
without passing through a  Ly6Chi monocyte state [124]. 
However, this transition is rapid during inflammation [73] 
and may have been missed at a 48 h time point, since Ly6C 
on monocytes and T cells is crucial for endothelial transmi-
gration [44, 145, 146, 166, 310]. Nevertheless, this high-
lights the continuing development of our understanding of 
myeloid cell differentiation and responses in the pathogen-
esis of EAE and other neuroinflammatory diseases.
While monocytes evidently acquire a multitude of phe-
notypes in EAE, the inflammatory microenvironment 
appears to be critical in shaping the functional specializa-
tion of these subsets and their contribution to pathology. 
This may include cytokines, such as GM-CSF, that are pro-
duced by autoreactive T cells surrounding inflammatory 
lesions. Indeed, GM-CSF signalling is thought to induce a 
characteristic transcriptional signature in monocytes that is 
sufficient to drive disease onset [67, 190]. Monocytes with 
defective GM-CSF signalling do not participate in myelin 
destruction [135], suggesting the pathogenic activity of this 
subset is contingent on GM-CSF signalling by autoreactive 
T cells. Temporal and spatial factors in the inflammatory 
microenvironment further contribute to the functional 
specialization of infiltrating monocyte-derived cells. For 
instance, fate-mapping experiments of infiltrating phago-
cytes revealed that pro-inflammatory polarization  (iNOS+) 
of these cells occurred predominantly in the spinal cord 
lesions [201] and perivascular space [177], whereas those 
expressing an anti-inflammatory phenotype (arginase-1+) 
resided predominantly in the meninges [164, 201].  iNOS+ 
cells expressing this characteristic pro-inflammatory signa-
ture predominated during the formation of lesions [201], 
but as lesions progressed towards resolution  iNOS+ cells 
locally adapted their phenotype and transitioned towards an 
anti-inflammatory phenotype that was thought to guide EAE 
recovery [201]. When injected into the healthy CNS, these 
pro-inflammatory  iNOS+ cells shifted their phenotype to an 
anti-inflammatory  Arg1+ phenotype within a few days [201], 
strongly supporting the notion that the local CNS environ-
ment mediates this phenotypic switch. Indeed, in the absence 
of lesion resolution, monocyte-derived cells expressing an 
anti-inflammatory phenotype may return to a pro-inflamma-
tory state in response to a chronic inflammatory environment 
[124], perhaps reflecting a transcriptional adaptation to the 
complex inflammatory lesion environment in which damage 
and regeneration are concurrent.
Concluding remarks
CNS inflammation is an accompanying pathological feature 
of neurological diseases that can lead to neurodegeneration 
and progressive neurological deficits. Although multiple 
immune cell types can inflict injury within the CNS paren-
chyma, resident and infiltrating myeloid cells are key regu-
lators of disease outcome. However, elucidating the precise 
contributions of each cell subset to neurological diseases 
has historically been hampered by the paucity of research 
tools available to accurately identify these cells in human 
and murine tissue. The development of new reagents and 
experimental systems has greatly improved our ability to dis-
tinguish resident from infiltrating myeloid cells in inflamma-
tion, unravelling the interplay and division of labor between 
these cell subsets in disease.
In summary, we have highlighted the non-redundant and 
often opposing mechanisms by which monocytes and micro-
glia dampen or exacerbate immunopathology in murine and 
human studies of autoimmune neuroinflammation, CNS 
injury, and viral encephalitis. Although more human stud-
ies are required, findings from animal models suggest that 
both cell types can perform both protective and pathogenic 
functions, with microglia overall more protective in the 
acute phase of viral encephalitis and stroke, and seemingly 
more pathogenic in diseases with chronic neuroinflamma-
tion, including AD and MS, as well as in the recovery phase 
Acta Neuropathologica 
1 3
of viral infection. In contrast, the functions of monocyte-
derived cells are not as clear-cut. These cells can perform 
protective functions that enhance viral clearance and tissue 
repair, however, and in general, monocyte infiltration occurs 
at the expense of detrimental tissue damage, albeit in many 
cases, priming the tissue for repair.
The inherent limitations of animal models must be con-
sidered when extrapolating findings to human disease. None-
theless, this review has emphasized the critical importance 
of animal studies in understanding certain elements of CNS 
pathology. Currently translating our understanding of mono-
cyte and microglial diversity into clinically useful therapeu-
tic approaches remains a significant challenge. Accurately 
identifying temporally dependent myeloid phenotypes and 
their associated protective or pathological functions, both 
unique and common to various CNS pathologies, remains 
a crucial goal of current research. The Grail is in the pre-
cise, confident tailoring and harnessing of this specific 
knowledge.
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